Document:

Exhibit
10.3

 

SECURITIES
PURCHASE AGREEMENT

 

THIS
SECURITIES PURCHASE AGREEMENT (the “Agreement”), is entered into as of July 30, 2020 (the “Execution
Date”), by and between 27 Health Holdings Corp., a Nevada corporation (the “Company”), and the Buyer
identified on the signature page hereto (the “Buyer”). The Company and Buyer are sometimes referred to individually,
as a “Party” and collectively, as the “Parties.”

 

WHEREAS,
the Company and the Buyer is executing and delivering this Agreement in reliance upon the exemption from securities registration
afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the “1933 Act”), and Rule 506(b) of
Regulation D (“Regulation D”) as promulgated by the United States Securities and Exchange Commission (the “SEC”)
under the 1933 Act.

 

WHEREAS,
the Company has authorized a new series of convertible preferred stock of the Company designated as Series N Convertible Preferred
Stock, the terms of which are set forth in the certificate of designation for such series of preferred stock (the “Certificate
of Designations”) in the form attached hereto as Exhibit A (together with any convertible preferred stock issued
in replacement thereof in accordance with the terms thereof, the “Preferred Shares”), which Preferred Shares
shall be convertible into the Company’s common stock, par value $0.001 per share (the “Common Stock”)
in accordance with the terms of the Certificate of Designations.

 

WHEREAS,
the Buyer wishes to purchase, and the Company wishes to sell, upon the terms and conditions stated in this Agreement, (i) that
aggregate number of Preferred Shares set forth on the Buyer’s signature page, Buyer and (ii) Warrants, in substantially
the form attached hereto as Exhibit B (the “Warrants”), representing the right to acquire that number
of shares of Common Stock set forth on the Buyer’s signature page (as exercised, collectively, the “Warrant Shares”).
The shares of Common Stock issuable pursuant to the terms of the Preferred Shares are referred to herein as the “Conversion
Shares”.

 

WHEREAS,
the Preferred Shares, the Warrants, the Conversion Shares and the Warrant Shares are collectively referred to herein as the “Securities.”

 

NOW,
THEREFORE, in consideration of the foregoing premises, and the promises and covenants herein contained, the receipt and sufficiency
of which are hereby acknowledged by the parties hereto, the Company and the Buyer, intending to be legally bound, hereby agree
as follows:

 

1.
PURCHASE AND SALE OF PREFERRED SHARES AND WARRANTS.

 

(a)
Preferred Shares and Warrants. Subject to the satisfaction (or waiver) of the conditions set forth in Sections 6 and 7
below, the Company agrees to issue and sell to the Buyer, and the Buyer agrees to purchase from the Company (the “Closing”)
on the Closing Date (as defined below), (x) the number of Preferred Shares, as is set forth on the Buyer’s signature page,
and (y) Warrants to acquire up to that number of Warrant Shares as is set forth on the Buyer’s signature page. The Preferred
Shares and the Warrants are collectively referred to in this Agreement as the “Securities.”

 

(b)
Closing. The date and time of the Closing (the “Closing Date”) shall be 10:00 a.m., New York City time,
on the Execution Date (or such later date as is mutually agreed to by the Company and the Buyer) after notification of satisfaction
(or waiver) of the conditions to the Closing set forth in Sections 6 and 7 below, at the offices of Nason, Yeager, Gerson, Harris
& Fumero, P.A., 3001 PGA Boulevard, Suite 305, Palm Beach Gardens, FL 33410.

 

(c)
Purchase Price. The aggregate purchase price for the Preferred Shares to be purchased by the Buyer (the “Purchase
Price”) shall be $405,000 reflecting a 10% original issuance discount from the stated value of $1,000 per share multiplied
by the 450 Preferred Shares issued pursuant to this Agreement.

 

    	 

    	 

    

 

(d)
Time of Funding. On or before the Closing Date, (A) the Buyer shall deliver to the Company $250,000 (the “Initial
Purchase Price”), to be paid in cash to the Company for the Preferred Shares and Warrants to be issued and sold to the Buyer
at the Closing, by wire transfer of immediately available funds in accordance with the Company’s written wire instructions,
and (B) the Company shall deliver to the Buyer 278 Preferred Shares and 450,000 Warrants which the Buyer is purchasing hereunder,
in each case duly executed on behalf of the Company and registered in the name of the Buyer or its designee. On the 90th day following
the Closing, (A) the Buyer shall deliver to the Company the final installment of $155,000 as the remainder of the Purchase Price
(the “Subsequent Purchase Price”), to be paid in cash by wire transfer of immediately available funds in accordance
with the Company’s written wire instructions and (B) the Company shall deliver to the Buyer the remaining 172 Preferred
Shares which the Buyer is purchasing hereunder, duly executed on behalf of the Company and registered in the name of the Buyer
or its designee (the “Subsequent Purchase”); provided, however, the Subsequent Purchase and the Buyer’s
obligation to pay the Subsequent Purchase Price arising therefrom shall be subject to (i) the Company’s Common Stock being
listed or quoted on the Principal Market as of such date, (ii) the Company’s delivery to the Buyer of updated secretary’s
and officer’s certificates in accordance with Section 7(d) and Section 7(e) each dated as of such date, (iii) the delivery
to the Buyer of an updated opinion of the Company’s counsel in accordance with Section 7(i) dated as of such date, and (iv)
the execution and delivery to the Buyer of an updated reservation letter with the Company’s transfer agent in accordance
with Section 7(j) dated as of such date; provided, further, that the Buyer shall not be obligated to fund the Subsequent
Purchase if there are any changes reflected in the documents deliverable under (ii) and (iii) which are not acceptable to the
Buyer.

 

2.
BUYER’S REPRESENTATIONS AND WARRANTIES.

 

The
Buyer represents and warrants as of the Execution Date and as of the Closing Date, that:

 

(a)
Organization; Authority. The Buyer is an entity duly organized, validly existing and in good standing under the laws of
the jurisdiction of its organization with the requisite power and authority to enter into and to consummate the transactions contemplated
by the Transaction Documents (as defined in Section 3(b) below) to which it is a party and otherwise to carry out its obligations
hereunder and thereunder.

 

(b)
No Public Sale or Distribution. The Buyer is (i) acquiring the Preferred Shares and the Warrants, (ii) upon conversion
of the Preferred Shares will acquire the Conversion Shares and (iii) upon exercise of the Warrants will acquire the Warrant Shares
issuable upon exercise of the Warrants, in each case, for its own account and not with a view towards, or for resale in connection
with, the public sale or distribution thereof, except pursuant to sales registered or exempted under the 1933 Act; provided, however,
that by making the representations herein, the Buyer does not agree to hold any of the Securities for any minimum or other specific
term and reserves the right to dispose of the Securities at any time in accordance with or pursuant to a registration statement
or an exemption under the 1933 Act. The Buyer is acquiring the Securities hereunder in the ordinary course of its business. The
Buyer does not presently have any agreement or understanding, directly or indirectly, with any Person (as defined below) to distribute
any of the Securities. For purposes of this Agreement, “Person” means an individual, a limited liability company,
a partnership, a joint venture, a corporation, a trust, an unincorporated organization and a government or any department or agency
thereof.

 

(c)
Accredited Buyer Status. The Buyer is an “accredited Buyer” as that term is defined in Rule 501(a) of Regulation
D promulgated under the 1933 Act.

 

(d)
Reliance on Exemptions. The Buyer understands that the Securities are being offered and sold to it in reliance on specific
exemptions from the registration requirements of United States federal and state securities laws and that the Company is relying
in part upon the truth and accuracy of, and the Buyer’s compliance with, the representations, warranties, agreements, acknowledgments
and understandings of the Buyer set forth herein in order to determine the availability of such exemptions and the eligibility
of the Buyer to acquire the Securities.

 

(e)
Information. The Buyer and its advisors, if any, have been furnished with all materials relating to the business, finances
and operations of the Company and materials relating to the offer and sale of the Securities that have been requested by the Buyer
in writing. The Buyer and its advisors, if any, have been afforded the opportunity to ask questions of the Company. Neither such
inquiries nor any other due diligence investigations conducted by the Buyer or its advisors, if any, or its representatives shall
modify, amend or affect the Buyer’s right to rely on the Company’s representations and warranties contained herein.
The Buyer understands that its investment in the Securities involves a high degree of risk. The Buyer has sought such accounting,
legal and tax advice as it has considered necessary to make an informed investment decision with respect to its acquisition of
the Securities.

 

    	2

    	 

    

 

(f)
No Governmental Review. The Buyer understands that no United States federal or state agency or any other government or
governmental agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of
the investment in the Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities.

 

(g)
Transfer or Resale. The Buyer understands that: (i) the Securities have not been and are not being registered under the
1933 Act or any state securities laws, and may not be offered for sale, sold, assigned or transferred unless (A) subsequently
registered thereunder, (B) the Buyer shall have delivered to the Company an opinion of counsel, in a generally acceptable form,
to the effect that such Securities to be sold, assigned or transferred may be sold, assigned or transferred pursuant to an exemption
from such registration, or (C) the Buyer provides the Company with reasonable assurance that such Securities can be sold, assigned
or transferred pursuant to Rule 144 promulgated under the 1933 Act, as amended, (or a successor rule thereto) (collectively, “Rule
144”) (which shall in no event include an opinion of counsel of the Buyer unless the reasonable fees of such counsel
are paid by the Company); (ii) any sale of the Securities made in reliance on Rule 144 may be made only in accordance with the
terms of Rule 144 and further, if Rule 144 is not applicable, any resale of the Securities under circumstances in which the seller
(or the Person through whom the sale is made) may be deemed to be an underwriter (as that term is defined in the 1933 Act) may
require compliance with some other exemption under the 1933 Act or the rules and regulations of the SEC thereunder; and (iii)
neither the Company nor any other Person is under any obligation to register the Securities under the 1933 Act or any state securities
laws or to comply with the terms and conditions of any exemption thereunder. Notwithstanding the foregoing, the Securities may
be pledged in connection with a bona fide margin account or other loan or financing arrangement secured by the Securities and
such pledge of Securities shall not be deemed to be a transfer, sale or assignment of the Securities hereunder, and no Buyer effecting
a pledge of Securities shall be required to provide the Company with any notice thereof or otherwise make any delivery to the
Company pursuant to this Agreement or any other Transaction Document (as defined in Section 3(b)), including, without limitation,
this Section 2(g).

 

(h)
Legends.

 

(i)
The Buyer understands that the certificates or other instruments representing the Preferred Shares and the Warrants, until such
time as the resale of the Conversion Shares and the Warrant Shares have been registered under the 1933 Act, the stock certificates
representing the Conversion Shares and the Warrant Shares, except as set forth below, shall bear a restrictive legend in substantially
the following form (and a stop-transfer order may be placed against transfer of such stock certificates):

 

[NEITHER
THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE [CONVERTIBLE][EXERCISABLE]
HAVE BEEN][THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN] REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED,
OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE
OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION
OF COUNSEL, IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE
144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN
ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

 

    	3

    	 

    

 

At
any time after the Execution Date, the legend set forth above shall be removed and the Company shall issue a certificate without
such legend to the holder of the Securities upon which it is stamped or, if available, issue to such holder by electronic delivery
at the applicable balance account at The Depository Trust Company (“DTC”), if (i) such Securities are registered
for resale under the 1933 Act, (ii) in connection with a sale, assignment or other transfer (other than pursuant to Rule 144),
such holder provides the Company with an opinion of counsel, in a generally acceptable form, to the effect that such sale, assignment
or transfer of the Securities may be made without registration under the applicable requirements of the 1933 Act, or (iii) the
Securities can be sold, assigned or transferred pursuant to Rule 144 without the need to comply with public information requirements
or volume limitations. The Company shall be responsible for the fees of its transfer agent, legal counsel to the Company and the
Buyer (including, without limitation, with respect to any legal opinion upon any sale pursuant to Rule 144) and all DTC fees associated
with such issuance.

 

(i)
Validity; Enforcement. This Agreement and the other Transaction Documents to which the Buyer is a party have been duly
and validly authorized, executed and delivered on behalf of the Buyer and shall constitute the legal, valid and binding obligations
of the Buyer enforceable against the Buyer in accordance with their respective terms, except as such enforceability may be limited
by general principles of equity or to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar
laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies.

 

(j)
No Conflicts. The execution, delivery and performance by the Buyer of this Agreement and the other Transaction Documents
to which the Buyer is a party and the consummation by the Buyer of the transactions contemplated hereby and thereby will not (i)
result in a violation of the organizational documents of the Buyer or (ii) conflict with, or constitute a default (or an event
which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment,
acceleration or cancellation of, any agreement, indenture or instrument to which the Buyer is a party, or (iii) result in a violation
of any law, rule, regulation, order, judgment or decree (including federal and state securities laws) applicable to the Buyer,
except in the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights or violations which would not, individually
or in the aggregate, reasonably be expected to have a material adverse effect on the ability of the Buyer to perform its obligations
hereunder.

 

(k)
No Bad Actor Disqualification Event. The Buyer represents, after reasonable inquiry, that none of the “Bad Actor”
disqualifying events described in Rule 506(d)(l)(i) to (viii) under the 1933 Act (a “Disqualification Event”)
is applicable to the Buyer or any of its Rule 506(d) Related Parties (if any), except a Disqualification Event as to which Rule
506(d)(2)(ii) or (iii) or (d)(3) applies. “Rule 506(d) Related Party” means a person or entity that is a beneficial
owner of the Buyer’s securities for purposes of Rule 506(d).

 

3.
REPRESENTATIONS AND WARRANTIES OF THE COMPANY. The Company represents and warrants to the Buyer, which representations
and warranties shall be true and correct as of the Execution Date and as of the Closing Date:

 

(a)
Organization and Qualification. Each of the Company and its “Subsidiaries” (which for purposes of this
Agreement means any joint venture or any entity in which the Company, directly or indirectly, owns more than 10% of the capital
stock or holds an equivalent equity or similar interest) are entities duly organized and validly existing and in good standing
under the laws of the jurisdiction in which they are formed, and have the requisite power and authorization to own their properties
and to carry on their business as now being conducted. Each of the Company and its Subsidiaries is duly qualified as a foreign
entity to do business and is in good standing in every jurisdiction in which its ownership of property or the nature of the business
conducted by it makes such qualification necessary, except to the extent that the failure to be so qualified or be in good standing
would not reasonably be expected to have a Material Adverse Effect. As used in this Agreement, “Material Adverse Effect”
means any material adverse effect on the business, properties, assets, operations, results of operations, condition (financial
or otherwise) or prospects of the Company and its Subsidiaries, individually or taken as a whole, or on the transactions contemplated
hereby or in the other Transaction Documents or by the agreements and instruments to be entered into in connection herewith or
therewith, or on the authority or ability of the Company to perform its obligations under the Transaction Documents. As used in
this Agreement, any adverse event that does not have a long-term effect on the Company is not a Material Adverse Effect. For purposes
of this subsection, “long-term effect” means an effect lasting more than six months. The Company has no Subsidiaries,
except as set forth on Schedule 3(a).

 

    	4

    	 

    

 

(b)
Authorization; Enforcement; Validity. The Company has the requisite corporate power and authority to enter into and perform
its obligations under this Agreement, the Certificate of Designations, the Warrants, and each of the other agreements entered
into by the parties hereto in connection with the transactions contemplated by this Agreement (collectively, the “Transaction
Documents”) and to issue the Securities in accordance with the terms hereof and thereof. The execution and delivery
of the Transaction Documents by the Company and the consummation by the Company of the transactions contemplated hereby and thereby,
including, without limitation, the issuance of the Preferred Shares and Warrants and the reservation for issuance and the issuance
of the Conversion Shares issuable upon conversion of the Preferred Shares and the reservation for issuance and issuance of Warrant
Shares issuable upon exercise of the Warrants have been duly authorized by the Company’s Board of Directors and no further
filing, consent, or authorization is required by the Company, its board of directors or its stockholders. This Agreement and the
other Transaction Documents of even date herewith have been duly executed and delivered by the Company, and constitute the legal,
valid and binding obligations of the Company, enforceable against the Company in accordance with their respective terms, except
as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium,
liquidation or similar laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies.
The Certificate of Designation in the form attached hereto as Exhibit A has been filed with the Secretary of State of the
State of Nevada and is in full force and effect, enforceable against the Company in accordance with its terms.

 

(c)
Issuance of Securities. The issuance of the Preferred Shares and the Warrants have been duly authorized and upon issuance
in accordance with the terms of the Transaction Documents shall be validly issued and free from all taxes, liens and charges with
respect to the issue thereof, and the Preferred Shares shall be entitled to the rights and preferences set forth in the Certificate
of Designations. Beginning simultaneous with the Closing, the Company shall at all times reserve from its duly authorized capital
stock not less than the sum of 400% of the maximum number of shares of Common Stock issuable (i) upon conversion of the maximum
number of Preferred Shares (assuming for purposes hereof, that the Preferred Shares are convertible at the Conversion Price (as
defined in the Certificate of Designations) and without taking into account any limitations on the conversion of the Preferred
Shares set forth in the Certificate of Designations) and (ii) upon exercise of the Warrants (without taking into account any limitations
on the exercise of the Warrants set forth in the Warrants), in each case, determined as if issued as of the trading day immediately
preceding the applicable date of determination, it being understood that the reservation of stock by the Company is a material
obligation of the Company, and the failure of the Company to reserve sufficient stock under this Section 3(c) at any time shall
constitute a default under this Agreement and entitle the Buyer to pursue all remedies available under this Agreement and the
Transaction Documents. Upon issuance or conversion in accordance with the Certificate of Designations or the exercise of the Warrants
and payment of the exercise price under the Warrants (including by Cashless Exercise) thereunder, the Conversion Shares and the
Warrant Shares, respectively, will be validly issued, fully paid and nonassessable and free from all preemptive or similar rights,
taxes, liens and charges with respect to the issue thereof, with the holders being entitled to all rights accorded to a holder
of Common Stock. Assuming the accuracy of each of the representations and warranties set forth in Section 2 of this Agreement,
the offer and issuance by the Company of the Securities is exempt from registration under the 1933 Act.

 

(d)
No Conflicts. The execution, delivery and performance of the Transaction Documents by the Company and the consummation
by the Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Preferred
Shares and the Warrants, and reservation for issuance and issuance of the Conversion Shares and the Warrant Shares) will not (i)
result in a violation of any articles of incorporation, any certificate of formation, any certificate of designations or other
constituent documents of the Company or any of its Subsidiaries, any capital stock of the Company or any of its Subsidiaries or
the bylaws of the Company or any of its Subsidiaries or (ii) conflict with, or constitute a default (or an event which with notice
or lapse of time or both would become a default) in any respect under, or give to others any rights of termination, amendment,
acceleration or cancellation of, any agreement, indenture or instrument to which the Company or any of its Subsidiaries is a party,
or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including foreign, federal and state laws
and regulations) applicable to the Company or any of its Subsidiaries or by which any property or asset of the Company or any
of its Subsidiaries is bound or affected.

 

(e)
Consents. Neither the Company nor any of its Subsidiaries is required to obtain any consent, authorization or order of,
or make any filing or registration with, any government, court, regulatory, self-regulatory, administrative agency or commission
or other governmental agency, authority or instrumentality, domestic or foreign, of competent jurisdiction (a “Governmental
Authority”) or any other Person in order for it to execute, deliver or perform any of its obligations under or contemplated
by the Transaction Documents, in each case in accordance with the terms hereof or thereof, except for (i) the filing of a Form
D pursuant to Regulation D promulgated by the SEC under the 1933 Act and (ii) the filings required by applicable state “blue
sky” securities laws, rules and regulations. The Company and its Subsidiaries are unaware of any facts or circumstances
that might prevent the Company from obtaining or effecting any of the registration, application or filings pursuant to the preceding
sentence.

 

    	5

    	 

    

 

(f)
Acknowledgment Regarding Buyer’s Purchase of Securities. The Company acknowledges and agrees that the Buyer is acting
solely in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the transactions contemplated
hereby and thereby and that no Buyer is (i) an officer or director of the Company or any of its Subsidiaries, or (ii) an “affiliate”
(as defined in Rule 144) of the Company or any of its Subsidiaries. The Company further acknowledges that no Buyer is acting as
a financial advisor or fiduciary of the Company or any of its Subsidiaries (or in any similar capacity) with respect to the Transaction
Documents and the transactions contemplated hereby and thereby, and any advice given by the Buyer or any of its representatives
or agents in connection with the Transaction Documents and the transactions contemplated hereby and thereby is merely incidental
to the Buyer’s purchase of the Securities. The Company further represents to the Buyer that the Company’s decision
to enter into the Transaction Documents has been based solely on the independent evaluation by the Company and its representatives.

 

(g)
No General Solicitation; Placement Agent. Neither the Company, nor any of its Subsidiaries or affiliates, nor any Person
acting on its or their behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation
D) in connection with the offer or sale of the Securities. Neither the Company nor any of its Subsidiaries has engaged any placement
agent or other agent in connection with the sale of the Securities. In the event that a broker-dealer or other agent or advisory
is engaged by the Company subsequent to the initial Closing, the Company shall be responsible for the payment of any placement
agent’s fees, financial advisory fees, or brokers’ commissions (other than for persons engaged by the Buyer or its
investment advisor) relating to or arising out of the transactions contemplated hereby in connection with the sale of the Securities.
The Company shall pay, and hold the Buyer harmless against, any liability, loss or expense (including, without limitation, attorney’s
fees and out-of-pocket expenses) arising in connection with any such claim.

 

(h)
No Integrated Offering. None of the Company, its Subsidiaries, any of their affiliates, and any Person acting on their
behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under
circumstances that would require registration of any of the Securities under the 1933 Act, whether through integration with prior
offerings or otherwise, or caused this offering of the Securities to require approval of stockholders of the Company for purposes
of any applicable stockholder approval provisions, including, without limitation, under the rules and regulations of any exchange
or automated quotation system on which any of the securities of the Company are listed or designated, but excluding stockholder
consents required to authorize and issue the Securities or waive any anti-dilution provisions in connection therewith. None of
the Company, its Subsidiaries, their affiliates and any Person acting on their behalf will take any action or steps referred to
in the preceding sentence that would require registration of any of the Securities under the 1933 Act or cause the offering of
the Securities to be integrated with other offerings for purposes of any such applicable stockholder approval provisions.

 

(i)
Dilutive Effect. The Company understands and acknowledges that the number of Conversion Shares issuable upon conversion
of the Preferred Shares and the number of Warrant Shares issuable upon exercise of the Warrants will increase in certain circumstances.
The Company further acknowledges that its obligation to issue Conversion Shares upon conversion of the Preferred Shares in accordance
with this Agreement and the Certificate of Designations, and its obligation to issue the Warrant Shares upon exercise of the Warrants
in accordance with this Agreement and the Warrants, is, in each case, not limited by the dilutive effect that such issuance may
have on the ownership interests of other stockholders of the Company.

 

(j)
Application of Takeover Protections; Rights Agreement. Other than as disclosed on Schedule 3(j), the Company and
its board of directors have taken all necessary action, if any, in order to render inapplicable any control share acquisition,
business combination, poison pill (including any distribution under a rights agreement) or other similar anti-takeover provision
under the Articles of Incorporation, (as defined in Section 3(r)) any certificates of designations or the laws of the jurisdiction
of its formation or incorporation which is or could become applicable to the Buyer as a result of the transactions contemplated
by this Agreement, including, without limitation, the Company’s issuance of the Securities and the Buyer’s ownership
of the Securities. The Company and its board of directors have taken all necessary actions, if any, in order to render inapplicable
any stockholder rights plan or similar arrangement relating to accumulations of beneficial ownership of Common Stock or a change
in control of the Company. The Parties understand and acknowledge that the Company has authorized and issued and outstanding certain
series of preferred stock, par value $0.001 per share which contain anti-dilution provisions and super-majority voting rights
which may limit anti-takeover effects, which the Parties agree will not be adversely effected by this Section 3(j).

 

    	6

    	 

    

 

(k)
Material Liabilities; Financial Statements. The Company has no liabilities or obligations, absolute or contingent (individually
or in the aggregate), except (i) liabilities and obligations incurred after April 30, 2020 in the ordinary course of business,
including the execution of convertible notes issued in the ordinary course of the Company’s business operations and past
practices and (ii) obligations under contracts made in the ordinary course of business that would not be required to be reflected
in financial statements prepared in accordance with generally accepted accounting principles as applied in the United States,
consistently applied for the periods covered thereby (“GAAP”). The financial statements of the Company for
the three and nine months ended April 30, 2020 and 2019 (including, in each case, any related notes thereto), as filed with the
SEC (the “Financial Statements”), are correct and complete in all material respects and such statements fairly
present in all material respects the financial position of the Company and its Subsidiaries, on a consolidated basis, at the respective
dates thereof and the results of its operations and cash flows for the periods indicated. The Financial Statements do not contain
any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to
make the statements therein, in light of the circumstances under which they were made, not misleading.

 

(l)
Absence of Certain Changes. Since April 30, 2020, there has been no material adverse change and no material adverse development
in the business, assets, properties, operations, condition (financial or otherwise), results of operations or prospects of the
Company or its Subsidiaries. Without limiting the generality of the foregoing, neither the Company nor any of its Subsidiaries
has:

 

(i)
declared, set aside or paid any dividend or other distribution with respect to any shares of capital stock of the Company or any
of its Subsidiaries or any direct or indirect redemption, purchase or other acquisition of any such shares;

 

(ii)
sold, assigned, pledged, encumbered, transferred or otherwise disposed of any tangible asset of the Company or any of its Subsidiaries
(other than sales or the licensing of its products to customers in the ordinary course of business consistent with past practice),
or sold, assigned, pledged, encumbered, transferred or otherwise disposed of any Intellectual Property (other than licensing of
products of the Company or its Subsidiaries in the ordinary course of business and on a non-exclusive basis);

 

(iii)
entered into any licensing or other agreement with regard to the disposition of any Intellectual Property (as hereinafter defined)
other than licenses in the ordinary course of business consistent with past practice or any amendment or consent with respect
to any licensing agreement filed or required to be filed with respect to any Governmental Authority;

 

(iv)
made any capital expenditures, individually or in the aggregate, in excess of $25,000, other than in the ordinary course of business
or as disclosed in Schedule 3(l)(iv);

 

(v)
other than as disclosed in Schedule 3(l)(v) or in the ordinary course of business, incurred any obligation or liability (whether
absolute, accrued, contingent or otherwise, and whether due or to become due) incurred by the Company or any of its Subsidiaries,
in excess of $25,000 individually, other than obligations under customer contracts, current obligations and liabilities, in each
case incurred in the ordinary course of business and consistent with past practice;

 

(vi)
incurred any Lien on any property of the Company or any of its Subsidiaries except for Permitted Liens and Liens in existence
on the date of this Agreement that are described on Schedule 3(s);

 

    	 	7	 

     

    

 

(vii)
made any payment, discharge, satisfaction or settlement of any suit, action, claim, arbitration, proceeding or obligation of the
Company or any of its Subsidiaries, except in the ordinary course of business and consistent with past practice;

 

(viii)
effected any split, combination or reclassification of any equity securities;

 

(ix)
sustained any material loss, destruction or damage to any property of the Company or any Subsidiary, whether or not insured;

 

(x)
effected any acceleration or prepayment of any Indebtedness (as defined below) for borrowed money or the refunding of any such
Indebtedness other than at terms advantageous to the Company;

 

(xi)
experienced any labor trouble involving the Company or any Subsidiary or any material change in their personnel or the terms and
conditions of employment;

 

(xii)
made any waiver of any valuable right, whether by contract or otherwise;

 

(xiii)
made any loan or extension of credit to any officer or employee of the Company;

 

(xiv)
made any change in the independent public accountants of the Company or its Subsidiaries or any material change in the accounting
methods or accounting practices followed by the Company or its Subsidiaries, as applicable, or any material change in depreciation
or amortization policies or rates;

 

(xv)
experienced any resignation or termination of any officer, key employee or group of employees of the Company or any of its Subsidiaries,
except as disclosed in Schedule 3(l)(xv);

 

(xvi)
effected any change in any compensation arrangement or agreement with any employee, officer, director or stockholder that would
result in the aggregate compensation to such Person in such year to exceed $25,000;

 

(xvii)
effected any material increase in the compensation of employees of the Company or its Subsidiaries (including any increase pursuant
to any written bonus, pension, profit sharing or other benefit or compensation plan, policy or arrangement or commitment), or
any increase in any such compensation or bonus payable to any officer, stockholder, director, consultant or agent of the Company
or any of its Subsidiaries having an annual salary or remuneration in excess of $25,000;

 

(xviii)
made any revaluation of any of their respective assets, including, without limitation, writing down the value of capitalized inventory
or writing off notes or accounts receivable or any sale of assets other than in the ordinary course of business;

 

(xix)
effected any acquisition or disposition of any material assets (or any contract or arrangement therefor), or any other material
transaction by the Company or any Subsidiary otherwise than for fair value in the ordinary course of business except as disclosed
in Schedule 3(l)(xix);

 

(xx)
written-down the value of any asset of the Company or its Subsidiaries or written-off as uncollectible of any accounts or notes
receivable or any portion thereof except in the ordinary course of business and in a magnitude consistent with historical practice;

 

(xxi)
cancelled any debts or claims or any material amendment, termination or waiver of any rights of the Company or its Subsidiaries;
or

 

(xxii)
entered into any agreement, whether in writing or otherwise, to take any of the actions specified in the foregoing items (i) through (xxii).

 

    	8

    	 

    

 

Notwithstanding
the foregoing, the Company acknowledges that it is indebted to a family member of the Company’s CEO in the amount of $50,000,
which it intends to repay but will not use the proceeds from this Agreement to repay this obligation. The Parties agree that this
obligation does not constitute a violation of the representations in Section 3(l) or any other sections or provisions of this
Agreement

 

Neither
the Company nor any of its Subsidiaries has taken any steps to seek protection pursuant to any bankruptcy law nor does the Company
have any Knowledge or reason to believe that its creditors intend to initiate involuntary bankruptcy proceedings or any Knowledge
of any fact that would reasonably lead a creditor to do so.

 

(m)
No Undisclosed Events, Liabilities, Developments or Circumstances. The Company and its Subsidiaries have no liabilities
or obligations of any nature (whether accrued, absolute, contingent, unasserted or otherwise and whether due or to become due)
other than those liabilities or obligations that are disclosed in the Financial Statements or which do not exceed, individually
in excess of $50,000 and in the aggregate in excess of $100,000, other than under convertible notes executed subsequent to the
filing with the SEC on June 22, 2020 of the Company’s financial statements for the period ended April 30, 2020. The reserves,
if any, established by the Company or the lack of reserves, if applicable, are reasonable based upon facts and circumstances known
by the Company on the Execution Date and there are no loss contingencies that are required to be accrued by the Statement of Financial
Accounting Standard No. 5 of the Financial Accounting Standards Board which are not provided for in the Financial Statements.

 

(n)
Conduct of Business; Regulatory Permits. Neither the Company nor any of its Subsidiaries is in violation of any term of
or in default under its Articles of Incorporation, the Certificate of Designations, any other certificate of designation, preferences
or rights of any other outstanding series of preferred stock of the Company or the Bylaws (as defined in Section 3(r)) or their
organizational charter or Articles of Incorporation or bylaws, respectively. Neither the Company nor any of its Subsidiaries is
in violation of any judgment, decree or order or any statute, ordinance, rule or regulation (each a “Legal Requirement”)
applicable to the Company or any of its Subsidiaries, and neither the Company nor any of its Subsidiaries will conduct its business
in violation of any of the foregoing, except for possible violations which could not, individually or in the aggregate, reasonably
be expected to have a Material Adverse Effect. The Company and its Subsidiaries possess all certificates, authorizations and permits
issued by the appropriate regulatory authorities necessary to conduct their respective businesses, except where the failure to
possess such certificates, authorizations or permits would not have, individually or in the aggregate, a Material Adverse Effect,
and neither the Company nor any such Subsidiary has received any notice of proceedings relating to the revocation or modification
of any such certificate, authorization or permit. There is no agreement, commitment, judgment, injunction, order or decree binding
upon the Company or any of its Subsidiaries or to which the Company or any of its Subsidiaries is a party which has or could reasonably
be expected to have the effect of prohibiting or materially impairing any business practice of the Company or any of its Subsidiaries,
any acquisition of property by the Company or any of its Subsidiaries or the conduct of business by the Company or any of its
Subsidiaries as currently conducted other than such effects, individually or in the aggregate, which have not had and could not
reasonably be expected to have a Material Adverse Effect on the Company or any of its Subsidiaries.

 

(o)
Foreign Corrupt Practices. Neither the Company nor any of its Subsidiaries nor any director, officer, agent, employee or
other Person acting on behalf of the Company or any of its Subsidiaries has, in the course of its actions for, or on behalf of,
the Company or any of its Subsidiaries (i) used any corporate funds for any unlawful contribution, gift, entertainment or other
unlawful expenses relating to political activity; (ii) made any direct or indirect unlawful payment to any foreign or domestic
government official or employee from corporate funds; (iii) violated or is in violation of any provision of the U.S. Foreign Corrupt
Practices Act of 1977, as amended; or (iv) made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful
payment to any foreign or domestic government official or employee.

 

(p)
Management. During the past 10 year period ^, no current ^ officer or director or, to the Knowledge of the Company, stockholder
of the Company or any of its Subsidiaries has been the subject of:

 

(i)
a petition under bankruptcy laws or any other insolvency or moratorium law or has a receiver, fiscal agent or similar officer
been appointed by a court for such Person, or any partnership in which such person was a general partner at or within two years
before the time of such filing, or any corporation or business association of which such person was an executive officer at or
within two years before the time of such filing;

 

    	9

    	 

    

 

(ii)
a conviction in a criminal proceeding or a named subject of a pending criminal proceeding (excluding traffic violations that do
not relate to driving while intoxicated or driving under the influence);

 

(iii)
any order, judgment or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently
or temporarily enjoining any such person from, or otherwise limiting, the following activities:

 

(1)
Acting as a futures commission merchant, introducing broker, commodity trading advisor, commodity pool operator, floor broker,
leverage transaction merchant, any other person regulated by the United States Commodity Futures Trading Commission or an associated
person of any of the foregoing, or as an investment adviser, underwriter, broker or dealer in securities, or as an affiliated
person, director or employee of any investment company, bank, savings and loan association or insurance company, or engaging in
or continuing any conduct or practice in connection with such activity;

 

(2)
Engaging in any type of business practice; or

 

(3)
Engaging in any activity in connection with the purchase or sale of any security or commodity or in connection with any violation
of securities laws or commodities laws;

 

(iv)
any order, judgment or decree, not subsequently reversed, suspended or vacated, of any authority barring, suspending or otherwise
limiting for more than 60 days the right of any such person to engage in any activity described in the preceding sub paragraph,
or to be associated with persons engaged in any such activity;

 

(v)
finding by a court of competent jurisdiction in a civil action or by the SEC or other authority to have violated any securities
law, regulation or decree and the judgment in such civil action or finding by the SEC or any other authority has not been subsequently
reversed, suspended or vacated; or

 

(vi)
a finding by a court of competent jurisdiction in a civil action or by the Commodity Futures Trading Commission to have violated
any federal commodities law, and the judgment in such civil action or finding has not been subsequently reversed, suspended or
vacated.

 

(q)
Transactions With Affiliates. Except as disclosed in the Company’s filings with the SEC under the Exchange Act, no
current employee, director, officer of the Company or its Subsidiaries, affiliate of any thereof or any relative with a relationship
no more remote than first cousin of any of the foregoing other than as set forth in the paragraph under Section 3(l)(xxii) above,
is presently, or has ever been, since the change of control of the Company and the reconstituting of the Company’s Board
of Directors, as disclosed in the Company’s Form 8-K filed on January 27, 2020, including exhibits thereto, (i) a party
to any transaction with the Company or its Subsidiaries (including any contract, agreement or other arrangement providing for
the furnishing of services by, or rental of real or personal property from, or otherwise requiring payments to, any such director,
officer or stockholder or such associate or affiliate or relative (but excluding any employment or consulting contract with the
Company) or (ii) the direct or indirect owner of an interest in any corporation, firm, association or business organization which
is a competitor, supplier or customer of the Company or its Subsidiaries (except for a passive investment (direct or indirect)
in less than 5% of the common stock of a company whose securities are publicly traded on or quoted), nor does any such Person
receive income from any source other than the Company or its Subsidiaries which relates to the business of the Company or its
Subsidiaries or should properly accrue to the Company or its Subsidiaries. As used in this Agreement, “Knowledge”
has the meaning ascribed it in Section 9(r). No employee, officer, stockholder or director of the Company or any of its Subsidiaries
or member of his or her immediate family is indebted to the Company or its Subsidiaries, as the case may be, nor is the Company
or any of its Subsidiaries indebted (or committed to make loans or extend or guarantee credit) to any of them, other than (i)
for payment of salary for services rendered, (ii) reimbursement for reasonable expenses incurred on behalf of the Company, and
(iii) for other standard employee benefits made generally available to all employees or executives (including stock option agreements
outstanding under any stock option plan approved by the board of directors of the Company).

 

    	10

    	 

    

 

(r)
Equity Capitalization. As of the Execution Date, the authorized capital stock of the Company consists of (i) 900,000,000
shares of Common Stock, of which 1,056,700 shares are issued and outstanding; (ii) 100,000,000 shares of Common Stock are reserved
for issuance pursuant to the Company’s 2018 Equity Incentive Plan ( a “Plan”); (iii) 1,950 shares of
Series A Convertible Preferred Stock and 1,000,000 shares of Series B Convertible Preferred Stock, in each case $0.001 par value
per share, of which 1,000,001 shares are issued and outstanding; (iv) 20 shares of Series L Convertible Preferred Stock, of which
a total of 18 shares are issued and outstanding, (v) 60,000 shares of Series G Convertible Preferred Stock, of which a total of
1950 shares are issued and outstanding, (vi) 40,000,000 shares of Series F Convertible Preferred Stock, of which 10,000 shares
are issued and outstanding, and (vii) 375 shares of Series T Convertible Preferred Stock, of which 0 shares are issued and outstanding.
All of the Company’s outstanding shares have been, or upon issuance will be, validly issued and fully paid and nonassessable.
As of the Execution Date, (i) none of the Company’s capital stock is subject to preemptive rights or any other similar rights
or any liens or encumbrances suffered or permitted by the Company; (ii) there are no outstanding options, warrants, scrip, rights
to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into, or exercisable
or exchangeable for, any capital stock of the Company or any of its Subsidiaries, or contracts, commitments, understandings or
arrangements by which the Company or any of its Subsidiaries is or may become bound to issue additional capital stock of the Company
or any of its Subsidiaries or options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever
relating to, or securities or rights convertible into, or exercisable or exchangeable for, any capital stock of the Company or
any of its Subsidiaries; (iii) there are no outstanding debt securities, notes, credit agreements, credit facilities or other
agreements, documents or instruments evidencing Indebtedness of the Company or any of its Subsidiaries or by which the Company
or any of its Subsidiaries is or may become bound; (iv) there are no financing statements securing obligations in any material
amounts, either singly or in the aggregate, filed in connection with the Company or any of its Subsidiaries; (v) there are no
agreements or arrangements under which the Company or any of its Subsidiaries is obligated to register the sale of any of their
securities under the 1933 Act; (vi) there are no outstanding securities or instruments of the Company or any of its Subsidiaries
which contain any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by
which the Company or any of its Subsidiaries is or may become bound to redeem a security of the Company or any of its Subsidiaries;
(vii) there are no securities or instruments containing anti-dilution or similar provisions that will be triggered by the issuance
of the Securities; (viii) the Company has not issued any stock appreciation rights or “phantom stock” or any similar
rights; and (ix) the Company and its Subsidiaries have no liabilities or obligations required to be disclosed in the Financial
Statements in accordance with GAAP but not so disclosed in the Financial Statements. As of the Closing Date, no Indebtedness or
outstanding securities of the Company is or will be senior to the Preferred Shares in right of payment, whether with respect to
interest or upon liquidation or dissolution, other than indebtedness secured by purchase money security interests (which is senior
only as to underlying assets covered thereby) and capital lease obligations (which is senior only as to the property covered thereby).
Notwithstanding the foregoing, the Parties understand that the Company filed an Information Statement on Schedule PRE 14C on July
10, 2020, to: (i) increase the authorized Preferred Stock from 100 million shares to 200 million shares; and (ii) change the name
of the Company from Lord Global Corporation to 27 Health Holdings Corp.

 

(s)
The Company has furnished to the Buyer true, correct and complete copies of the Company’s articles of incorporation, as
amended and as in effect on the date hereof (the “Articles of Incorporation”), and the Company’s Bylaws,
as amended and as in effect on the date hereof (the “Bylaws”), and the terms of all securities convertible
into, or exercisable or exchangeable for, shares of Common Stock and the material rights of the holders thereof in respect thereto.

 

    	11

    	 

    

 

(t)
Indebtedness and Other Contracts. Except for Permitted Liens and as disclosed on Schedule 3(t), neither the Company
nor any of its Subsidiaries (i) has any outstanding Indebtedness (as defined below) other than as set forth in the paragraph
under Section 3(l)(xxii) above, (ii) is a party to any contract, agreement or instrument, the violation of which, or default under
which, by the other party(ies) to such contract, agreement or instrument could reasonably be expected to result in a Material
Adverse Effect, (iii) is in violation of any term of or in default under any contract, agreement or instrument relating to any
Indebtedness, except where such violations and defaults would not result, individually or in the aggregate, in a Material Adverse
Effect, or (iv) is a party to any contract, agreement or instrument relating to any Indebtedness, the performance of which, in
the judgment of the Company’s officers, has or is expected to have a Material Adverse Effect. Schedule 3(t) provides
a description of the material terms of any such outstanding Indebtedness. For purposes of this Agreement: (x) “Indebtedness”
of any Person means, without duplication (A) all indebtedness for borrowed money, (B) all obligations issued, undertaken or assumed
as the deferred purchase price of property or services (including, without limitation, “capital leases” in accordance
with GAAP) (other than trade payables entered into in the ordinary course of business consistent with past practice), (C) all
reimbursement or payment obligations with respect to letters of credit, surety bonds and other similar instruments, (D) all obligations
evidenced by notes, bonds, debentures or similar instruments, including obligations so evidenced incurred in connection with the
acquisition of property, assets or businesses, (E) all indebtedness created or arising under any conditional sale or other title
retention agreement, or incurred as financing, in either case with respect to any property or assets acquired with the proceeds
of such indebtedness (even though the rights and remedies of the seller or bank under such agreement in the event of default are
limited to repossession or sale of such property), (F) all monetary obligations under any leasing or similar arrangement which,
in GAAP, consistently applied for the periods covered thereby, is classified as a capital lease, (G) all indebtedness referred
to in clauses (A) through (F) above secured by (or for which the holder of such Indebtedness has an existing right, contingent
or otherwise, to be secured by) any mortgage, deed of trust, lien, pledge, charge, security interest, easement, covenant, right
of way, restriction, equity or encumbrance of any nature whatsoever in or upon any property or assets (including accounts and
contract rights) with respect to any asset (a “Lien”) owned by any Person, even though the Person which owns
such assets or property has not assumed or become liable for the payment of such indebtedness, and (H) all Contingent Obligations
in respect of indebtedness or obligations of others of the kinds referred to in clauses (A) through (G) above; and (y) “Contingent
Obligation” means, as to any Person, any direct or indirect liability, contingent or otherwise, of that Person with
respect to any indebtedness, lease, dividend or other obligation of another Person if the primary purpose or intent of the Person
incurring such liability, or the primary effect thereof, is to provide assurance to the obligee of such liability that such liability
will be paid or discharged, or that any agreements relating thereto will be complied with, or that the holders of such liability
will be protected (in whole or in part) against loss with respect thereto.

 

(u)
Absence of Litigation. There is no action, suit, arbitration or other legal, administrative or other governmental investigation,
inquiry or proceeding (whether federal, state, local or foreign) pending or, to the best of the Company’s Knowledge, threatened
against or affecting the Company or any of its Subsidiaries or any of their respective properties, assets, capital stock or businesses
or any of the Company’s or any of its Subsidiaries’ officers or directors. After reasonable inquiry of its employees,
the Company is not aware of any fact which might result in or form the basis for any such action, suit, arbitration, investigation,
inquiry or other proceeding. Neither the Company nor any of its Subsidiaries is subject to any order, writ, judgment, injunction,
decree, determination or award of any Governmental Authority.

 

(v)
Employee Matters; Benefit Plans.

 

(i)
The employment of each officer and employee of the Company is terminable at the will of the Company. The Company and its Subsidiaries
have complied in all material respects with all applicable laws relating to wages, hours, equal opportunity, collective bargaining,
workers’ compensation insurance and the payment of social security and other taxes. As of the Execution Date (i) the Company
is not aware that any officer, key employee or group of employees intends to terminate his, her or their employment with the Company
or its Subsidiaries, as the case may be, nor does (ii) the Company have a present intention, or know of a present intention of
its Subsidiaries, to terminate the employment of any officer, key employee or group of employees. There are no pending or, to
the Knowledge of the Company, threatened employment discrimination charges or complaints against or involving the Company or its
Subsidiaries before any federal, state, or local board, department, commission or agency, or unfair labor practice charges or
complaints, disputes or grievances affecting the Company or its Subsidiaries.

 

    	12

    	 

    

 

(ii)
Since the Company’s inception, to the Knowledge of the Company neither the Company nor its Subsidiaries has experienced
any labor disputes, union organization attempts or work stoppage due to labor disagreements. There are no unfair labor practice
charges or complaints against the Company or its Subsidiaries pending, or to the Knowledge of the Company, threatened before the
National Labor Relations Board or any comparable state agency or authority. There are no written or oral contracts, commitments,
agreements, understandings or other arrangements with any labor organization, nor work rules or practices agreed to with any labor
organization or employee association, applicable to employees of the Company or any of its Subsidiaries, nor is the Company or
its Subsidiaries a party to, or bound by, any collective bargaining or similar agreement; there is not, and since the Company’s
inception there has not been, any representation of the employees of the Company or its Subsidiaries by any labor organization
and, to the Knowledge of the Company, there are no union organizing activities among the employees of the Company or its Subsidiaries,
and to the Knowledge of the Company, no question concerning representation has been raised or is threatened respecting the employees
of the Company or its Subsidiaries.

 

(iii)
Schedule 3(v)(iii) contains a true, correct and complete list of each pension, retirement, savings, deferred compensation
and profit-sharing plan and each stock option, stock appreciation, stock purchase, performance share, bonus or other incentive
plan, severance plan, health, group insurance or other welfare plan, or other similar plan (whether written or otherwise) and
any “employee benefit plan” within the meaning of Section 3(3) of the Employee Retirement Income Security Act of 1974,
as amended (“ERISA”), under which the Company has any current or future obligation or liability (including
any potential, contingent or secondary liability under Title IV of ERISA) or under which any employee or former employee (or beneficiary
of any employee or former employee) of the Company has or may have any current or future right to benefits (the term “plan”
shall include any contract, agreement (including an employment or independent contractor agreement), policy or understanding,
each such plan being hereinafter referred to in this Agreement individually as a “Benefit Plan”). The Company
has delivered to the Buyer true, correct and complete copies of (i) each material Benefit Plan, including any amendments thereto,
(ii) the summary plan description, if any, for each Benefit Plan, including any summaries of material modifications made since
the most recent summary plan description, (iii) the latest annual report which has been filed with the Internal Revenue Service
(the “IRS”) for each Benefit Plan required to file an annual report, and (iv) the most recent IRS determination
letter for each Benefit Plan that is a pension plan (as defined in ERISA) intended to be qualified under Section 401(a) of the
Internal Revenue Code of 1986, as amended (the “Code”). Each Benefit Plan intended to be tax qualified under
Sections 401(a) and 501(a) of the Code is and has been determined by the IRS to be tax qualified under Sections 401(a) and 501(a)
of the Code and, since such determination, no amendment to or failure to amend any such Benefit Plan and no other event or circumstance
has occurred that could reasonably be expected to adversely affect its tax qualified status.

 

(iv)
There are no actions, claims, audits, lawsuits or arbitrations pending, or, to the Knowledge of the Company, threatened, with
respect to any Benefit Plan or the assets of any Benefit Plan. Each Benefit Plan has been administered in all material respects
in accordance with its terms and with all applicable Legal Requirements (including, without limitation, the Code and ERISA).

 

(v)
The consummation of the transactions contemplated by this Agreement will not (1) entitle any employee or independent contractor
of the Company or its Subsidiaries to severance pay or termination benefits, (2) accelerate the time of payment or vesting, or
increase the amount of compensation due to any current or former employee or independent contractor of the Company or its Subsidiaries,
(3) obligate the Company or any of its affiliates to pay or otherwise be liable for any compensation, vacation days, pension contribution
or other benefits to any current or former employee, consultant, agent or independent contractor of the Company or its Subsidiaries
for periods before the Closing Date, (4) require assets to be set aside or other forms of security to be provided with respect
to any liability under a Benefit Plan, or (5) result in any “parachute payment” (within the meaning of Section 280G
of the Code) under any Benefit Plan.

 

(vi)
No Benefit Plan is subject to the provisions of Section 412 of the Code or Part 3 of Subtitle B of Title I of ERISA. No Benefit
Plan is subject to Title IV of ERISA and no Benefit Plan is a “multiemployer plan” (within the meaning of Section
3(37) of ERISA). Since inception, neither the Company, its Subsidiaries, nor any business or entity treated as a single employer
with the Company or its Subsidiaries for purposes of Title IV of ERISA contributed to or was obliged to contribute to a pension
plan that was at any time subject to Title IV of ERISA.

 

(vii)
No Benefit Plan has provided, been required to provide, provides or is required to provide, at any time in the past, present,
or future, health, medical, dental, accident, disability, death or survivor benefits to or in respect of any Person beyond one
year following termination of employment, except to the extent required under any state insurance law or under Part 6 of Subtitle
B of Title I of ERISA and under Section 4980B of the Code. No Benefit Plan covers any individual that is not an employee or advisor
of the Company or its Subsidiaries, other than spouses and dependents of employees under health and child care policies, true
and complete copies of which have been made available to the Buyer.

 

    	13

    	 

    

 

Except
as otherwise permitted pursuant to employment agreements with the Company disclosed to the Buyer, each officer of the Company
is currently devoting all of such officer’s business time to the conduct of the business of the Company. Except as otherwise
permitted pursuant to employment agreements with the Company disclosed to the Buyer, the Company is not aware of any officer or
key employee of the Company or any of its Subsidiaries planning to work less than full time at the Company or its Subsidiaries
in the future

 

(w)
Assets; Title.

 

(i)
Each of the Company and its Subsidiaries has good and valid title to, a valid license to, or a valid leasehold interest in, as
applicable, all of its properties and assets, free and clear of all Liens except (i) any Lien for taxes not yet due or delinquent
or being contested in good faith by appropriate proceedings for which adequate reserves have been established in accordance with
GAAP, (ii) any statutory Lien arising in the ordinary course of business by operation of law with respect to a liability that
is not yet due or delinquent, (iii) any Lien created by operation of law, such as materialmen’s liens, mechanics’
liens and other similar liens, arising in the ordinary course of business with respect to a liability that is not yet due or delinquent
or that are being contested in good faith by appropriate proceedings, and (iv) such as have been terminated in the ordinary course
of business (collectively, “Permitted Liens”). To the Company’s Knowledge, all tangible personal property
owned by the Company and its Subsidiaries has been maintained in good operating condition and repair, except (x) for ordinary
wear and tear, and (y) where such failure would not have a Material Adverse Effect. To the Company’s Knowledge, all assets
leased by the Company or any of its Subsidiaries are in the condition required by the terms of the lease applicable thereto during
the term of such lease and upon the expiration thereof. To the Company’s Knowledge, the Company and its Subsidiaries have
good and marketable title in fee simple to all real property and good and marketable title to all personal property owned by them
which is material to the business of the Company and its Subsidiaries, in each case free and clear of all liens, encumbrances
and defects. Any real property and facilities held under lease by the Company or any of its Subsidiaries are held by them under
valid, subsisting and enforceable leases with such exceptions as are not material and do not interfere with the use made and proposed
to be made of such property and buildings by the Company and its Subsidiaries.

 

(ii)
Schedule 3(w)(ii) sets forth a complete list of all real property and interests in real property, leased by the Company
as of the Execution Date. The Company has good and valid leasehold interest in all real property and interests in real property
shown on Schedule 3(w)(ii) to be leased by it free and clear of all Liens except for Permitted Liens or where such Liens
would not have a Material Adverse Effect. There exists no default, or any event which upon notice or the passage of time, or both,
would give rise to any default, in the performance of the Company or by any lessor under any such lease, nor, to the Knowledge
of the Company, is the landlord of any such lease in default except where any such default would not have a Material Adverse Effect.

 

(x)
Intellectual Property.

 

(i)
The Company and its Subsidiaries own all right, title and interest in and to, or have a valid and enforceable license to use all
the Intellectual Property used by them in connection with the their respective businesses, which, to the Company’s Knowledge,
represents all intellectual property rights necessary to the conduct of the Company’s business as now conducted. To the
Company’s Knowledge, the Company and its Subsidiaries are in material compliance with all contractual obligations relating
to the protection of such of the Intellectual Property as they use pursuant to license or other agreement. To the Company’s
Knowledge, the conduct of the business of the Company and its Subsidiaries as currently conducted or contemplated does not conflict
with or infringe any proprietary right or Intellectual Property of any third party, including, without limitation, the transmission,
reproduction, use, display or modification of any content or material (including framing, and linking web site content) on a web
site, bulletin board or other like medium hosted by or on behalf of the Company or any of its Subsidiaries, except for such infringements
and conflicts which could not reasonably be expected to have a Material Adverse Effect. To the Company’s Knowledge, there
is no claim, suit, action or proceeding pending or, to the Knowledge of the Company, threatened against the Company or any Subsidiary:
(i) alleging any such conflict or infringement with any third party’s proprietary rights; or (ii) challenging the Company’s
or any Subsidiary’s ownership or use of, or the validity or enforceability of any Intellectual Property.

 

    	14

    	 

    

 

(ii)
Schedule 3(x)(ii) sets forth a complete and current list of registered trademarks or copyrights, issued patents, applications
thereof, or other forms of registration anywhere in the world that is owned by the Company or a Subsidiary (“Listed Intellectual
Property”) and the owner of record, date of application or issuance and relevant jurisdiction as to each. To the Company’s
Knowledge, all Listed Intellectual Property is owned by the Company or a Subsidiary, free and clear of security interests, liens,
encumbrances or claims of any nature. To the Company’s Knowledge, all Listed Intellectual Property is valid, subsisting,
unexpired, in proper form and enforceable and all renewal fees and other maintenance fees that have fallen due on or prior to
the Execution Date have been paid. To the Company’s Knowledge, no Listed Intellectual Property is the subject of any proceeding
before any governmental, registration or other authority in any jurisdiction, including any office action or other form of preliminary
or final refusal of registration, except as noted on Schedule 3(x)(ii). To the Company’s Knowledge, the consummation
of the transactions contemplated hereby will not alter or impair in any material respect any Intellectual Property that is owned
or licensed by the Company or a Subsidiary.

 

(iii)
Schedule 3(x)(iii) sets forth a complete list of all material agreements relating to Intellectual Property to which the
Company or a Subsidiary is a party, subject or bound (the “Intellectual Property Contracts”) (other than agreements
involving (A) the license of the Company of standard, generally commercially available “off-the-shelf” third party
products or (B) non-disclosure agreements). To the Company’s Knowledge, each Intellectual Property Contract: (i) is valid
and binding on the Company or a Subsidiary, as the case may be, and, to the Company’s Knowledge, the counterparties thereto,
and is in full force and effect and (ii) upon consummation of the transactions contemplated hereby shall continue in full force
and effect without penalty or other adverse consequence.

 

(iv)
To the Company’s Knowledge, and except as disclosed on Schedule 3(x)(iv), the Company and its Subsidiaries are not
under any obligation to pay royalties or other payments in connection with any agreement, nor restricted from assigning their
rights respecting Intellectual Property nor will the Company or any Subsidiary otherwise be, as a result of the execution and
delivery of this Agreement or the performance of the Company’s obligations under this Agreement, in material breach of any
agreement relating to the Intellectual Property.

 

(v)
To the Company’s Knowledge, and except as disclosed on Schedule 3(x)(v), no present or former employee, officer or
director of the Company or any Subsidiary, or agent or outside contractor of the Company or any Subsidiary, holds any right, title
or interest, directly or indirectly, in whole or in part, in or to any Intellectual Property that is owned or licensed by the
Company or any Subsidiary.

 

(vi)
To the Company’s Knowledge, and except as disclosed on Schedule 3(x)(vi): (i) none of the Listed Intellectual Property
has been used, disclosed or appropriated to the detriment of the Company or any Subsidiary for the benefit of any Person other
than the Company; and (ii) no employee, independent contractor or agent of the Company or any Subsidiary has misappropriated any
trade secrets or other confidential information of any other Person in the course of the performance of his or her duties as an
employee, independent contractor or agent of the Company or any Subsidiary that would reasonably be expected to have a Material
Adverse Effect.

 

(vii)
To the Company’s Knowledge, and except as disclosed on Schedule 3(x)(vii), any programs, modifications, enhancements
or other inventions, improvements, discoveries, methods or works of authorship (“Works”) that were created
by employees of the Company or any Subsidiary were made in the regular course of such employees’ employment or service relationships
with the Company or its Subsidiary using the Company’s or the Subsidiary’s facilities and resources and, as such,
constitute either works made for hire or all rights and title to and in such Works have been fully assigned to the Company or
a Subsidiary.

 

    	15

    	 

    

 

(viii)
For the purpose of this Section 3(x), “Intellectual Property” shall mean all of the following: (A) trademarks
and service marks, trade dress, product configurations, trade names and other indications of origin, applications or registrations
in any jurisdiction pertaining to the foregoing and all goodwill associated therewith; (B) inventions, discoveries, improvements,
ideas, know-how, formula methodology, processes, technology, software (including password unprotected interpretive code or source
code, object code, development documentation, programming tools, drawings, specifications and data) and applications and patents
in any jurisdiction pertaining to the foregoing, including re-issues, continuations, divisions, continuations-in-part, renewals
or extensions; (C) trade secrets, including confidential information and the right in any jurisdiction to limit the use or disclosure
thereof; (D) copyrights in writings, designs software, mask works or other works, applications or registrations in any jurisdiction
for the foregoing and all moral rights related thereto; (E) database rights; (F) Internet Web sites, domain names and applications
and registrations pertaining thereto and all intellectual property used in connection with or contained in all versions of the
Company’s Web sites; (G) rights under all agreements relating to any of the foregoing; (H) books and records pertaining
to any of the foregoing; and (I) claims or causes of action arising out of or related to past, present or future infringement
or misappropriation of any of the foregoing.

 

(y)
Environmental Laws. To its Knowledge, the Company and its Subsidiaries (i) are in compliance with any and all Environmental
Laws (as hereinafter defined), (ii) have received all permits, licenses or other approvals required of them under applicable Environmental
Laws to conduct their respective businesses and (iii) are in compliance with all terms and conditions of any such permit, license
or approval where, in each of the foregoing clauses (i), (ii) and (iii), the failure to so comply would be reasonably expected
to have, individually or in the aggregate, a Material Adverse Effect. The term “Environmental Laws” means all
federal, state, local or foreign laws relating to pollution or protection of human health or the environment (including, without
limitation, ambient air, surface water, groundwater, land surface or subsurface strata), including, without limitation, laws relating
to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances
or wastes (collectively, “Hazardous Materials”) into the environment, or otherwise relating to the manufacture,
processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations,
codes, decrees, demands or demand letters, injunctions, judgments, licenses, notices or notice letters, orders, permits, plans
or regulations issued, entered, promulgated or approved thereunder.

 

(z)
Subsidiary Rights. The Company or one of its Subsidiaries has the unrestricted right to vote, and (subject to limitations
imposed by applicable law) to receive dividends and distributions on, all equity securities of its Subsidiaries as owned by the
Company or such Subsidiary.

 

(aa)
Tax Status.

 

(i)
Each of the Company and its Subsidiaries has filed or caused to be filed in a timely manner (within any applicable extension periods)
and in the appropriate jurisdictions all material returns, reports, information statements and other documentation (including
any additional or supporting materials) filed or maintained, or required to be filed or maintained, in connection with the calculation,
determination, assessment or collection of any and all federal, state, local, foreign and other taxes, levies, fees, imposts,
duties, governmental fees and charges of whatever kind (including any interest, penalties or additions to the tax imposed in connection
therewith or with respect thereto), including, without limitation, taxes imposed on, or measured by, income, franchise, profits,
gross income or gross receipts, and also ad valorem, value added, sales, use, service, real or personal property, capital
stock, stock transfer, license, payroll, withholding, employment, social security, workers’ compensation, unemployment compensation,
utility, severance, production, excise, stamp, occupation, premium, windfall profits, environmental, transfer and gains taxes
and customs duties (each a “Tax”) and shall include amended returns required as a result of examination adjustments
made by the IRS or other Governmental Authority responsible for the imposition of any Tax (collectively, the “Returns”)
and, to the Company’s Knowledge, such Returns are true, correct and complete in all material respects.

 

(ii)
To the Company’s Knowledge, each of the Company and its Subsidiaries has paid all material Taxes and other assessments due
from and payable by the Company and its Subsidiaries on or prior to the date hereof on a timely basis. The charges, accruals,
and reserves for Taxes with respect to the Company and its Subsidiaries are adequate to cover Tax liabilities of the Company and
its Subsidiaries accruing throughout the Execution Date. To the Company’s Knowledge, each of the Company and its Subsidiaries
has complied in all material respects with all applicable Legal Requirements relating to the payment and withholding of Taxes
(including withholding and reporting requirements under Sections 1441 through 1464, 3401 through 3406, and 6041 and 6049 of the
Code and similar provisions under any other applicable Legal Requirements) and, within the time and in the manner prescribed by
law, to the Company’s Knowledge, has withheld from wages, fees and other payments and paid over to the proper governmental
or regulatory authorities all amounts required. To the Company’s Knowledge, neither the Company nor any of its Subsidiaries
has received notice of assessment or proposed assessment of any Taxes claimed to be owed by it or any other Person on its behalf.
To the Company’s Knowledge, no Returns filed by or on behalf of the Company or any of its Subsidiaries with respect to Taxes
are currently being audited or examined. To the Company’s Knowledge, neither the Company nor any of its Subsidiaries has
received notice of any such audit or examination. To the Company’s Knowledge, no issue has been raised by any taxing authority
with respect to the Company or any of its Subsidiaries in any audit or examination which, by application of similar principles,
would reasonably be expected to result in a proposed material adjustment to the liability for Taxes for any period not so examined.

 

    	16

    	 

    

 

(iii)
To the Company’s Knowledge, no known Liens have been filed and no claims are being asserted by or against the Company or
any of its Subsidiaries with respect to any Taxes (other than Liens for Taxes not yet due and payable). Neither the Company nor
any of its Subsidiaries has elected pursuant to the Code to be treated as an S corporation or any comparable provision of local,
state or foreign law, or has made any other elections pursuant to the Code (other than elections that relate solely to entity
classification, methods of accounting, depreciation, or amortization) that would have a material effect on the business, properties,
prospects, or financial condition of the Company and its Subsidiaries, individually or in the aggregate.

 

(iv)
To the Company’s Knowledge, no claim has ever been made, or, to the Knowledge of the Company, is threatened or pending,
by any authority in a jurisdiction where the Company or any of its Subsidiaries, respectively, does not file Returns, and, to
the Company’s Knowledge, neither the Company nor any of its Subsidiaries has received any notice or request for information
from any such authority. Neither the Company nor any of its Subsidiaries has been a member of an affiliated group (as defined
in Section 1504(a) of the Code) or filed or been included in a combined, consolidated or unitary income tax return other than
the affiliated group of which the Company is currently the common parent. To the Company’s Knowledge, neither the Company
nor any of its Subsidiaries is required to include in income any adjustment pursuant to Section 481(a) of the Code by reason of
a voluntary change in accounting methods initiated by the Company or any of its Subsidiaries, and to the Company’s Knowledge,
no Governmental Authority has proposed an adjustment or change in accounting method. To the Company’s Knowledge, all transactions
or methods of accounting that could give rise to a substantial understatement of federal income tax as described in Section 6662(d)(2)(B)(i)
of the Code have been adequately disclosed on the Company’s and its Subsidiaries’ federal income tax returns in accordance
with Section 6662(d)(2)(B) of the Code. To the Company’s Knowledge, neither the Company nor any of its Subsidiaries is a
party to any Tax sharing or Tax indemnity agreement or any other agreement of a similar nature that remains in effect. To the
Company’s Knowledge, neither the Company nor any of its Subsidiaries has consented to any waiver of the statute of limitations
for the assessment of any Taxes or has requested any extension of time for the payment of any Taxes. To the Company’s Knowledge,
neither the Company nor any of its Subsidiaries has ever held a material beneficial interest in any other Person. To the Company’s
Knowledge, neither the Company nor any of its Subsidiaries is obligated to make, nor as a result of any event connected with the
transactions contemplated by this Agreement will become obligated to make, any payment that would not be deductible under Section
280G of the Code. Neither the Company nor any Subsidiary of the Company is a “passive foreign investment company”
within the meaning of Section 1296 of the Code (a “PFIC”), and the Company does not anticipate that the Company
or any additional foreign Subsidiary will become a PFIC in the foreseeable future.

 

(bb)
Internal Accounting and Disclosure Controls. The Company and each of its Subsidiaries maintain a system of internal accounting
controls appropriate for its size. However, the Company’s internal controls and disclosure controls are not effective as
disclosed in the Company’s Quarterly Report on Form 10-Q for the three months ended April 30, 2020.

 

(cc)
Off Balance Sheet Arrangements. There is no transaction, arrangement, or other relationship between the Company and an
unconsolidated or other off balance sheet entity that is not disclosed by the Company in its Financial Statements or that otherwise
would be reasonably likely to have a Material Adverse Effect.

 

(dd)
Investment Company Status. The Company is not, and upon consummation of the sale of the Securities will not be, an “investment
company,” a company controlled by an “investment company” or an “affiliated person” of, or “promoter”
or “principal underwriter” for, an “investment company” as such terms are defined in the Investment Company
Act of 1940, as amended.

 

    	17

    	 

    

 

(ee)
Illegal or Unauthorized Payments; Political Contributions. Neither the Company or any of its Subsidiaries nor, to the best
of the Company’s Knowledge (after reasonable inquiry of its officers and directors), any of the officers, directors, employees,
agents or other representatives of the Company or any of its Subsidiaries or any other business entity or enterprise with which
the Company or any Subsidiary is or has been affiliated or associated, has, directly or indirectly, made or authorized any payment,
contribution or gift of money, property, or services, whether or not in contravention of applicable law, (a) as a kickback or
bribe to any Person or (b) to any political organization, or the holder of or any aspirant to any elective or appointive public
office except for personal political contributions not involving the direct or indirect use of funds of the Company or any of
its Subsidiaries.

 

(ff)
Transfer Taxes. On the Closing Date, all stock transfer or other taxes (other than income or similar taxes) which are required
to be paid in connection with the sale and transfer of the Securities to be sold to the Buyer hereunder will be, or will have
been, fully paid or provided for by the Company, and all laws imposing such taxes will be or will have been complied with.

 

(gg)
Books and Records. To the Company’s knowledge, the books of account, ledgers, order books, records and documents
of the Company and its Subsidiaries accurately and completely reflect all information relating to the respective businesses of
the Company and its Subsidiaries, the nature, acquisition, maintenance, location and collection of each of their respective assets,
and the nature of all transactions giving rise to material obligations or accounts receivable of the Company or its Subsidiaries,
as the case may be, except where the failure to so reflect such information would not have a Material Adverse Effect. To the Company’s
Knowledge, the minute books of the Company and its Subsidiaries contain accurate records in all material respects of all meetings
and accurately reflect all other actions taken by the stockholders, boards of directors and all committees of the boards of directors,
and other governing Persons of the Company and its Subsidiaries, respectively.

 

(hh)
Money Laundering. The Company and its Subsidiaries are in compliance with, and have not previously violated, the USA PATRIOT
ACT of 2001 (the “PATRIOT Act”) and all other applicable U.S. and non-U.S. anti-money laundering laws and regulations,
including, but not limited to, the laws, regulations and Executive Orders and sanctions programs administered by the U.S. Office
of Foreign Assets Control (“OFAC”), including, but not limited, to (i) Executive Order 13224 of September 23,
2001 entitled, “Blocking Property and Prohibiting Transactions With Persons Who Commit, Threaten to Commit, or Support Terrorism”
(66 Fed. Reg. 49079 (2001)); and (ii) any regulations contained in 31 CFR, Subtitle B, Chapter V (collectively, the “Anti-Money
Laundering/OFAC Laws”).

 

(ii)
Acknowledgement Regarding Buyer’ Trading Activity. It is understood and acknowledged by the Company (a) (i) that
none of the Buyer have been asked by the Company or its Subsidiaries to agree, nor has the Buyer agreed with the Company or its
Subsidiaries, to desist from purchasing or selling, long and/or short, securities of the Company, or “derivative”
securities based on securities issued by the Company or to hold the Securities for any specified term; and (ii) that the Buyer
shall not be deemed to have any affiliation with or control over any arm’s length counter party in any “derivative”
transaction. The Company further understands and acknowledges that one or more Buyer may engage in hedging and/or trading activities
at various times during the period that the Securities are outstanding, including, without limitation, during the periods that
the value of the Conversion Shares and/or the Warrant Shares are being determined and (b) such hedging and/or trading activities,
if any, can reduce the value of the existing stockholders’ equity interest in the Company both at and after the time the
hedging and/or trading activities are being conducted. The Company acknowledges that such aforementioned hedging and/or trading
activities do not constitute a breach of any of the Transaction Documents.

 

(jj)
U.S. Real Property Holding Corporation. The Company is not, has never been, and so long as any Securities remain outstanding,
shall not become, a U.S. real property holding corporation within the meaning of Section 897 of the Internal Revenue Code of 1986,
as amended, and the Company shall so certify upon the Buyer’s request.

 

(kk)
Bank Holding Company Act. Neither the Company nor any of its Subsidiaries is subject to the Bank Holding Company Act of
1956, as amended (the “BHCA”) and to regulation by the Board of Governors of the Federal Reserve System (the
“Federal Reserve”). Neither the Company nor any of its Subsidiaries or affiliates owns or controls, directly
or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent (25%)
or more of the total equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither
the Company nor any of its Subsidiaries or affiliates exercises a controlling influence over the management or policies of a bank
or any entity that is subject to the BHCA and to regulation by the Federal Reserve.

 

    	18

    	 

    

 

(ll)
Shell Company Status. The Company is not and has never been a “shell company” within the meaning of Rule 144(i)(1)
promulgated under the 1933 Act.

 

(mm)
No Disqualification Events. With respect to Securities to be offered and sold hereunder in reliance on Rule 506 under the
1933 Act (“Regulation D Securities”), none of the Company, any of its predecessors, any affiliated issuer,
any director, executive officer, other officer of the Company participating in the offering hereunder, any beneficial owner of
20% or more of the Company’s outstanding voting equity securities, calculated on the basis of voting power, nor any promoter
(as that term is defined in Rule 405 under the 1933 Act) connected with the Company in any capacity at the time of sale (each,
an “Issuer Covered Person” and, together, “Issuer Covered Persons”) is subject to any Disqualification
Event, except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care to determine
whether any Issuer Covered Person is subject to a Disqualification Event. The Company has complied, to the extent applicable,
with its disclosure obligations under Rule 506(e), and has furnished to the Buyer a copy of any disclosures provided thereunder.

 

(nn)
Other Covered Persons. The Company is not aware of any Person (other than any Issuer Covered Person) that has been or will
be paid (directly or indirectly) remuneration for solicitation of Buyer or potential purchasers in connection with the sale of
any Regulation D Securities.

 

(oo)
Disclosure. The Company understands and confirms that the Buyer will rely on the foregoing representations in effecting
transactions in securities of the Company. No statement made by the Company in this Agreement, any other Transaction Document
or the Exhibits and Schedules attached hereto or in any certificate or schedule furnished or to be furnished by
or on behalf of the Company to the Buyer or any of their representatives in connection with the transactions contemplated hereby
contains any untrue statement of a material fact or omits to state a material fact necessary in order to make the statements contained
herein or therein not misleading. The due diligence materials previously provided by or on behalf of the Company to the Buyer
(the “Due Diligence Materials”), have been prepared in a good faith effort by the Company to describe the Company’s
present and proposed products, and projected growth and the Company and do not contain any untrue statement of a material fact
or omit to state a material fact necessary to make the statements therein not misleading, except that with respect to assumptions,
projections and expressions of opinion or predictions contained in the Due Diligence Materials, the Company represents only that
such assumptions, projections, expressions of opinion and predictions were made in good faith and that the Company believes there
is a reasonable basis therefor. To the Company’s Knowledge, the Due Diligence Materials contain all material agreements
of the Company and its Subsidiaries and no material agreements of the Company or its Subsidiaries exist other than those provided
in the Due Diligence Materials. The Company acknowledges and agrees that no Buyer participated in the preparation of, or has any
responsibility for, the content of any Due Diligence Materials.

 

(pp)
Absence of Schedules. In the event that on the Closing Date, the Company does not deliver and attached hereto any disclosure
schedule contemplated by this Agreement, the Company hereby acknowledges and agrees that (i) each such undelivered disclosure
schedule shall be deemed to read as follows: “Nothing to Disclose”, and (ii) the Buyer has not otherwise waived delivery
of such disclosure schedule.

 

(qq)
The holders of any stock, options or equity-based incentives issued under the Plan or any other compensatory arrangement have
entered into and are bound by a Lock-Up Agreement with the Company prohibiting them from disposing of such securities or underlying
Common Stock for a six-month period beginning on the Closing Date, substantially in the form attached hereto as Exhibit G

 

4.
COVENANTS.

 

(a)
Best Efforts. Each party shall use its best efforts to timely satisfy each of the covenants below and the conditions to
be satisfied by it as provided in Sections 6 and 7 of this Agreement.

 

    	19

    	 

    

 

(b)
Use of Proceeds. The Company shall use the proceeds from the sale of the Securities for working capital and other general
corporate purposes, including use of proceeds from the sale of the Securities for purposes consistent with the Company’s
disclosure in its filings with the SEC, and shall not, directly or indirectly, use such proceeds for any loan or advances to,
or investment in, any of its officers, directors or affiliates or any other corporation, partnership, enterprise or other Person.

 

(c)
Reporting Status. Until the date on which the Buyer or any transferee or assignee thereof to whom the Buyer assigns its
rights as a holder of Securities under this Agreement and/or the Certificate of Designations (each an “Investor”,
and collectively, the “Investors”) shall have sold all of the Conversion Shares, and Warrant Shares as applicable,
and none of the Preferred Shares or Warrants remain outstanding (the “Reporting Period”), the Company shall
timely file all reports required to be filed with the SEC pursuant to the Securities Exchange Act of 1934, as amended (the “1934
Act”), and the Company shall not terminate its status as an issuer required to file reports under the 1934 Act even
if the 1934 Act or the rules and regulations thereunder would no longer require or otherwise permit such termination, and the
Company shall take all actions necessary to permit it to, and thereafter to maintain its eligibility to, register the Conversion
Shares for resale by the Buyer on a registration statement on Form S-1 or Form S-3.

 

(d)
Financial Information. As long as any Securities remain outstanding, the Company agrees to send the following to each Investor
during the Reporting Period (i) unless the following are filed with the SEC through EDGAR and are available to the public through
the EDGAR system, within one Business Day after the filing thereof with the SEC, a copy of its Annual Reports on Form 10-K and
Quarterly Reports on Form 10-Q, any Current Reports on Form 8-K (or any analogous reports under the 1934 Act) and any registration
statements (other than on Form S-8) or amendments filed pursuant to the 1933 Act, (ii) on the same day as the release thereof,
e-mailed copies of all press releases issued by the Company or any of its Subsidiaries, and (iii) copies of any notices and other
information made available or given to the stockholders of the Company generally, contemporaneously with the making available
or giving thereof to the stockholders. As used herein, “Business Day” means any day other than Saturday, Sunday
or other day on which commercial banks in the City of New York are authorized or required by law to remain closed.

 

(e)
Listing. The Company shall promptly secure the listing or quotation of the Conversion Shares and Warrant Shares upon each
national securities exchange or trading market including the OTCQB, OTCQX, or OTC Pink Open Market (or successor markets), upon
which the Common Stock is then or on which it becomes listed (subject to official notice of issuance) or quoted (such primary
exchange or trading market, the “Principal Market”) and shall maintain, in accordance with this Agreement,
the listing or quotation of all additional Conversion Shares and Warrant Shares from time to time issued under the terms of the
Transaction Documents. The Company shall maintain the listing or quotation of the Conversion Shares and the Warrant Shares on
the Principal Market, and neither the Company nor any of its Subsidiaries shall take any action which would be reasonably expected
to result in the delisting or suspension of the Common Stock on the Principal Market. The Company shall pay all fees and expenses
in connection with satisfying its obligations under this Section 4(e).

 

(f)
Conditions of Issuance.

 

(i)
For a 45-day period beginning on the Closing Date, the Company shall not issue any securities.

 

(ii)
For a 45-day period beginning 45 days after the Closing Date, except for the transactions contemplated hereby, Exempt Issuances
or: (i) in connection with issuances pursuant to agreements with officers, directors, employees and consultants providing bona
fide services to the Company; (ii) issuances in connection with mergers, acquisitions, joint venture agreements or in furtherance
of the Company’s plan of operations; (iii) as part of its issuance and cancellation of series of preferred stock, the Company
shall not issue any Common Stock, preferred stock, Common Stock Equivalents or otherwise incur any Indebtedness. Notwithstanding
the foregoing, in the event that the Company intends to issue any shares of Common Stock, preferred stock, Common Stock Equivalents
in connection with any new financing transactions consistent with its past and ongoing business practices (“New Financing
Transaction(s)”), as long as any Securities remain outstanding, the Buyer shall have the right at its election in each New
Financing Transaction to participate to the extent of 40% of each New Financing Transaction (the “Buyer’s Participation
Rights”). In connection with the Buyer’s Participation Rights, the Company agrees that it shall give the Buyer not
less than five (5) business day’s email notice of each proposed New Financing Transaction (the “Participation Notice”)
and the Buyer, not less than two (2) business days after receipt of said Participation Notice, shall notify the Company by email
of its election to participate or not participate in the New Financing Transaction, as the same terms and conditions of such New
Financing Transaction.

 

    	20

    	 

    

 

(g)
Pledge of Securities. The Company acknowledges and agrees that the Securities may be pledged by an Investor in connection
with a bona fide margin agreement or other loan or financing arrangement that is secured by the Securities. The pledge of Securities
shall not be deemed to be a transfer, sale or assignment of the Securities hereunder, and no Investor effecting a pledge of Securities
shall be required to provide the Company with any notice thereof or otherwise make any delivery to the Company pursuant to this
Agreement or any other Transaction Document, including, without limitation, Section 2(g) hereof; provided that an Investor and
its pledgee shall be required to comply with the provisions of Section 2(g) hereof in order to effect a sale, transfer or assignment
of Securities to such pledgee. The Company hereby agrees to execute and deliver such documentation as a pledgee of the Securities
may reasonably request in connection with a pledge of the Securities to such pledgee by an Investor.

 

(h)
Disclosure of Transactions and Other Material Information. By 9:00 a.m., New York Time on the next Business Day immediately
following the date of this Agreement, the Company shall file a Current Report on Form 8-K describing all the material terms of
the transactions contemplated by the Transaction Documents in the form required by the 1934 Act and attaching all the material
Transaction Documents (including, without limitation, this Agreement and the forms of all exhibits to this Agreement) (including
all attachments and content required by the applicable disclosure regulations, the “8-K Filing”). From and
after the filing of the 8-K Filing, the Company shall have disclosed all material, non-public information (if any) provided to
any of the Buyer by the Company or any of its Subsidiaries or any of their respective officers, directors, employees or agents
in connection with the transactions contemplated by the Transaction Documents. In addition, effective upon the filing of the 8-K
Filing, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether
written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, affiliates, employees
or agents, on the one hand, and any of the Buyer or any of their affiliates, on the other hand, shall terminate. The Company shall
not, and shall cause each of its Subsidiaries and its and each of their respective officers, directors, employees and agents,
not to, provide the Buyer with any material, nonpublic information regarding the Company or any of its Subsidiaries from and after
the Execution Date without the express prior written consent of the Buyer. If the Buyer has, or believes it has, received any
such material, nonpublic information regarding the Company or any of its Subsidiaries, it may provide the Company with written
notice thereof. The Company shall, within two trading days of receipt of such notice, make public disclosure of such material,
nonpublic information. In the event of a breach of the foregoing covenant by the Company, any of its Subsidiaries, or any of its
or their respective officers, directors, employees and agents, in addition to any other remedy provided herein or in the Transaction
Documents, the Buyer shall have the right to make a public disclosure, in the form of a press release, public advertisement or
otherwise, of such material, nonpublic information without the prior approval by the Company, its Subsidiaries, or any of its
or their respective officers, directors, employees or agents. No Buyer shall have any liability to the Company, its Subsidiaries,
or any of its or their respective officers, directors, employees, stockholders or agents for any such disclosure. To the extent
that the Company delivers any material, non-public information to the Buyer without the Buyer’s consent, the Company hereby
covenants and agrees that the Buyer shall not have any duty of confidentiality with respect to, or a duty not to trade on the
basis of, such material, non-public information. Subject to the foregoing, neither the Company, its Subsidiaries nor the Buyer
shall issue any press releases or any other public statements with respect to the transactions contemplated hereby without the
consent of the Buyer; provided, however, that the Company shall be entitled, without the prior approval of the Buyer, to make
any press release or other public disclosure with respect to such transactions as is required by applicable law and regulations,
provided further that the Buyer shall be consulted by the Company in connection with any such press release or other public disclosure
prior to its release. Without the prior written consent of any applicable Buyer, neither the Company nor any of its Subsidiaries
or affiliates shall disclose the name of the Buyer in any filing, announcement, release or otherwise, except as the Company has
been advised by its counsel as may be required by law including the Rules of the SEC or in response to written comments of the
staff of the SEC. Notwithstanding the foregoing, in no event will the Company have an obligation to disclose any information which
the Buyer receives from a member of the Company’s Board of Directors that is an affiliate of the Buyer.

 

    	21

    	 

    

 

(i)
Corporate Existence. So long as the Buyer beneficially owns any Securities, the Company shall (i) maintain its corporate
existence and (ii) not be party to any Fundamental Transaction unless the Company is in compliance with the applicable provisions
governing Fundamental Transactions set forth in the Certificate of Designations and the Warrants. “Fundamental Transaction”
shall mean one in which (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation
of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any sale, lease, license, assignment,
transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions,
(iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed
pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or
property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly,
in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any
compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities,
cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share
purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off
or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of
the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making
or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or
other business combination).

 

(j)
Reservation of Shares. The Company shall take all action necessary to at all times have authorized, and reserved for the
purpose of issuance, no less than 400% of the maximum number of shares of Common Stock issuable (i) upon conversion of the maximum
number of Preferred Shares issued (assuming for purposes hereof, that the Preferred Shares are convertible at the Conversion Price
(as defined in the Certificate of Designations) and without taking into account any limitations on the conversion of the Preferred
Shares set forth in the Certificate of Designations) and (ii) upon exercise of the Warrants (without taking into account any limitations
on the exercise of the Warrants set forth in the Warrants), in each case, determined as if issued as of the trading day immediately
preceding the applicable date of determination (the “Required Reserved Amount”). If at any time the number
of shares of Common Stock authorized and reserved for issuance is not sufficient to meet the Required Reserved Amount, the Company
will promptly take all corporate action necessary to authorize and reserve a sufficient number of shares, including, without limitation,
calling a special meeting of stockholders to authorize additional shares to meet the Company’s obligations under Section
3(c), in the case of an insufficient number of authorized shares, obtain stockholder approval of an increase in such authorized
number of shares, and voting any treasury shares of the Company in favor of an increase in the authorized shares of the Company
to ensure that the number of authorized shares is sufficient to meet the Required Reserved Amount. In connection with any such
vote, the Buyer hereby agrees that it shall, if requested by the Company, vote all shares of capital stock held by the Buyer in
favor of any such increase in the authorized number of shares. In addition to any corporate action taken to authorize additional
shares, for so long as the number of shares of Common Stock authorized and reserved for issuance is not sufficient to meet the
Required Reserved Amount, the Company shall pay to the Buyer who submits to the Company a request for conversion of Preferred
Shares, which request cannot be fulfilled because of insufficient available shares, an amount in cash equal to $500 per day for
the initial 10 days that such Required Reserved Amount is not met, then $1,000 per day in cash, for each day thereafter until
such Required Reserved Amount is satisfied.

 

(k)
Conduct of Business. The business of the Company and its Subsidiaries shall not be conducted in violation of any law, ordinance
or regulation of any governmental entity, except where such violations would not result, either individually or in the aggregate,
in a Material Adverse Effect. The Company and its Subsidiaries shall at all times be in compliance with the Foreign Corrupt Practices
Act; the PATRIOT Act, and all other applicable U.S. and non-U.S. anti-money laundering laws and regulations; and the laws, regulations
and Executive Orders and sanctions programs administered by the OFAC, including, without limitation, the “Anti-Money Laundering/OFAC
Laws.”

 

    	22

    	 

    

 

(l)
Public Information. At any time during the period commencing on the Execution Date and ending two years from the Execution
Date, if (A) a registration statement is not available for the resale of all of the Securities and the Securities may not be sold
without restriction or limitation pursuant to Rule 144 and without the requirement to be in compliance with Rule 144(c)(1), if
the Company shall (i) fail for any reason to satisfy the requirements of Rule 144(c)(1), including, without limitation, the failure
to satisfy the current public information requirement under Rule 144(c) or (ii) if the Company becomes (or ever has been) an issuer
described in Rule 144(i)(1)(i), and the Company shall fail to satisfy any condition set forth in Rule 144(i)(2), and (B) any such
failure continues for more than 15 trading days (a “Public Information Failure”) then, as partial relief for
the damages to any holder of Securities by reason of any such delay in or reduction of its ability to sell the Securities (which
remedy shall not be exclusive of any other remedies available at law or in equity), the Company shall pay to each such holder
an amount in cash equal to one percent of the aggregate Purchase Price of such holder’s Securities (less any Common Stock
previously sold) on the day of a Public Information Failure and on every 30th day (pro-rated for periods totaling less than 30
days) thereafter until the earlier of (i) the date such Public Information Failure is cured and (ii) such time that such public
information is no longer required pursuant to Rule 144. The payments to which a holder shall be entitled pursuant to this Section
4(m) are referred to herein as “Public Information Failure Payments.” Public Information Failure Payments shall
be paid on the earlier of (I) the last day of the calendar month during which such Public Information Failure Payments are incurred
and (II) the second Business Day after the event or failure giving rise to the Public Information Failure Payments is cured. In
the event the Company fails to make Public Information Failure Payments in a timely manner, such Public Information Failure Payments
shall bear interest at the rate of one percent per month (prorated for partial months) until paid in full.

 

(m)
Additional Issuances of Securities.

 

(i)
For purposes of this Section 4(m), the following definitions shall apply.

 

(1)
“Common Stock Equivalents” means, collectively, Options and Convertible Securities.

 

(2)
“Convertible Securities” means any stock or securities, including convertible debt instruments (other than
Options) convertible into or exercisable or exchangeable for shares of Common Stock or preferred stock.

 

(3)
“Exempt Issuance” means any issuance, sale or exchange of (i) shares of Common Stock, restricted stock units
or standard options to purchase Common Stock issued to directors, officers, or employees (including bona fide consultants) of
the Company for services rendered to the Company in their capacity as such pursuant to a Plan or other agreement or arrangement,
with appropriate disclosure in the Company’s filings with the SEC, provided that the exercise price of any such options
is not lowered (except as a result of a stock dividend or stock split), none of such options are amended to increase the number
of shares issuable thereunder and none of the terms or conditions of any such options are otherwise materially changed in any
manner that adversely affects any of the Buyer; (ii) shares of Common Stock or preferred stock issued upon the conversion or exercise
of Convertible Securities (other than standard options to purchase Common Stock issued pursuant to a Plan that are covered by
clause (i) above) issued prior to the Execution Date or, if Convertible Securities are issued subsequent to the Execution Date,
the terms of such Convertible Securities, including but not limited to the conversion price or liquidation preference are in all
respects junior and subordinate to the rights and preferences of those granted the Buyer in the Transaction Documents provided
that the conversion price of any such Convertible Securities (other than standard options to purchase Common Stock issued pursuant
to a Plan that are covered by clause (i) above) is not lowered (other than in accordance with the terms thereof in effect as of
the Execution Date) from the conversion price in effect as of the Execution Date (whether pursuant to the terms of such Convertible
Securities or otherwise), none of such Convertible Securities (other than standard options to purchase Common Stock issued pursuant
to a Plan or other agreement or arrangement that are covered by clause (i) above) are amended to increase the number of shares
issuable thereunder and none of the terms or conditions of any such Convertible Securities (other than standard options to purchase
Common Stock issued pursuant to a Plan that are covered by clause (i) above) are otherwise materially changed in any manner that
adversely affects the Buyer; (iii) the shares of Common Stock issuable upon conversion of the Preferred Shares or otherwise pursuant
to the terms of the Certificate of Designations; provided, that the terms of the Certificate of Designations are not amended,
modified or changed on or after the Execution Date (other than anti-dilution adjustments pursuant to the terms thereof in effect
as of the Execution Date or, if amended after the Execution Date, the Company gives the Buyer five (5) Business Days prior written
notice of any anti-dilution adjustment terms), (iv) the shares of Common Stock issuable upon exercise of the Warrants or warrants
required to be issued under this Agreement pursuant to which the Preferred Shares were issued; provided, that the terms of the
Warrants and Warrants are not amended, modified or changed on or after the Execution Date (other than anti-dilution adjustments
pursuant to the terms thereof in effect as of the Execution Date or, if amended after the Execution Date, the Company gives the
Buyer five (5) Business Days prior written notice of any anti-dilution adjustment terms), or (v) securities issued pursuant to
a merger, acquisition, joint venture or similar transaction or agreement; provided that (A) the primary purpose of such issuance
is not to raise capital, (B) the primary purpose is for the purpose of generating revenues from existing business operations or
new lines of business, (C) the purchaser or acquirer of such securities in such issuance solely consists of either (1) the actual
participants in such transactions, (2) the actual owners of such assets or securities acquired in such merger, acquisition, joint
venture or similar transaction or agreement, (3) the shareholders, partners or members of the foregoing Persons and (4) Persons
whose primary business does not consist of investing in securities, and (D) the number or amount (as the case may be) of such
shares of Common Stock or preferred issued to such Person by the Company shall not be disproportionate to such Person’s
actual ownership of such assets or securities to be acquired or issued by the Company (as applicable).

 

    	23

    	 

    

 

(4)
“Options” means any rights, warrants or options to subscribe for or purchase Common Stock or Convertible Securities.

 

(5)
“Subsequent Placement” means, in connection with a financing transaction, any direct or indirect offer, sale,
grant of any option to purchase, or other disposition of (or announcement of any offer, sale, grant or any option to purchase
or other disposition of) any of the Company’s or its Subsidiaries’ equity, debt or equity equivalent securities, including
without limitation any debt, preferred stock or other instrument or security that is, at any time during its life and under any
circumstances, convertible into or exchangeable or exercisable for Common Stock or Common Stock Equivalents.

 

(ii)
Except as provided for herein, from the Closing Date until the earlier of the date (i) that is 24 months thereafter or (ii) the
date no Preferred Shares are outstanding, the Company will not, directly or indirectly, effect any Subsequent Placement unless
the Company shall have first complied with this Section 4(m)(ii).

 

(1)
The Company shall deliver to the Buyer an irrevocable written notice (the “Offer Notice”) of any proposed or
intended issuance or sale or exchange (the “Offer”) of the securities being offered (the “Offered
Securities”) in a Subsequent Placement not less than five (5) Business Days of the Company’s receipt of the terms
of a Subsequent Placement, which Offer Notice shall (w) identify and describe the Offered Securities, (x) describe the price and
other terms upon which they are to be issued, sold or exchanged, and the number or amount of the Offered Securities to be issued,
sold or exchanged, (y) identify the persons or entities (if known) to which or with which the Offered Securities are to be offered,
issued, sold or exchanged and any participating broker-dealer and (z) offer to issue and sell to the Buyer up to 40% of the Offered
Securities (at the Buyer’s election) with the Buyer having the right to purchase its pro rata portion (based on the Buyer’s
pro rata portion of the aggregate Investment Amount of Preferred Shares issued on the Closing Date) (the “Basic Amount”).
With respect to the Buyer that elects to purchase its Basic Amount, the Buyer may also indicate it will purchase or acquire any
additional portion of the Offered Securities attributable to the Basic Amounts of other Buyer should the other Buyer subscribe
for less than their Basic Amounts (the “Undersubscription Amount”), which process shall be repeated once until
the Buyer shall have an opportunity to subscribe for any remaining Undersubscription Amount. For the purposes of this Section
4(m)(ii)(1), an “Offer” shall not include any proposed or intended issuance or sale of securities in a strategic
transaction approved by a majority of the disinterested directors of the Company, provided that (A) any such issuance is only
to a Person which is, itself or through its subsidiaries, an operating company in a business synergistic with the business of
the Company and in which the Company receives benefits in addition to the investment of funds, (B) the primary purpose of such
issuance is not to raise capital, (C) the purchaser or acquirer of such securities in such issuance solely consists of either
(1) the actual participants in such strategic transactions, (2) the actual owners of such strategic assets or securities acquired
in such merger or acquisition, (3) the shareholders, partners or members of the foregoing Persons and (4) Persons whose primary
business does not consist of in investing in securities, and (D) the number or amount (as the case may be) of such securities
issued to such Person by the Company is not disproportionate to such Person’s actual participation in such strategic transactions
or ownership of such strategic assets or securities to be acquired by the Company (as applicable).

 

(2)
In addition to the right to purchase up to the 40% of the Offered Securities on a pro rata basis as described in Section 4(m)(ii)(1),
the Buyer shall also have the right to exchange its Securities that it then owns for the Offered Securities using the lowest price
for the Offered Securities that the Company is then offering (the “Exchange”).

 

    	24

    	 

    

 

(3)
To accept an Offer and/or the Exchange, in whole or in part, the Buyer must deliver a written notice to the Company prior to the
end of the third (3rd) Business Day after the Buyer’s receipt of the Offer Notice (the “Offer Period”),
setting forth the portion of the Buyer’s Basic Amount that the Buyer elects to purchase and, if the Buyer shall elect to
purchase all of its Basic Amount, the Undersubscription Amount, if any, that the Buyer elects to purchase (in either case, the
“Notice of Acceptance”). If the Basic Amounts subscribed for by all Buyer are less than the total of all of
the Basic Amounts, then the Buyer who has set forth an Undersubscription Amount in its Notice of Acceptance shall be entitled
to purchase, in addition to the Basic Amounts subscribed for, the Undersubscription Amount it has subscribed for; provided,
however, that if the Undersubscription Amounts subscribed for exceed the difference between the total of all the Basic
Amounts and the Basic Amounts subscribed for (the “Available Undersubscription Amount”), the Buyer who has
subscribed for any Undersubscription Amount shall be entitled to purchase only that portion of the Available Undersubscription
Amount as the Basic Amount of the Buyer bears to the total Basic Amounts of all Buyer that have subscribed for Undersubscription
Amounts, subject to rounding by the Company to the extent it deems reasonably necessary. Notwithstanding anything to the contrary
contained herein, if the Company desires to modify or amend the terms and conditions of the Offer prior to the expiration of the
Offer Period, the Company may deliver to the Buyer a new Offer Notice and the Offer Period shall expire on the fifth Business
Day after the Buyer’s receipt of such new Offer Notice. The same procedures and rights shall apply to any Exchange.

 

(4)
The Company shall have 20 Business Days from the expiration of the Offer Period above to offer, issue, sell or exchange all or
any part of such Offered Securities as to which a Notice of Acceptance has not been given by the Buyer (the “Refused
Securities”) pursuant to a definitive agreement (the “Subsequent Placement Agreement”) but only to
the offerees described in the Offer Notice (if so described therein) and only upon terms and conditions (including, without limitation,
unit prices and interest rates) that are not more favorable to the acquiring Person or Persons or less favorable to the Company
than those set forth in the Offer Notice and to publicly announce (a) the execution of such Subsequent Placement Agreement, and
(b) either (x) the consummation of the transactions contemplated by such Subsequent Placement Agreement or (y) the termination
of such Subsequent Placement Agreement, which shall be filed with the SEC on a Current Report on Form 8-K with such Subsequent
Placement Agreement and any documents contemplated therein filed as exhibits thereto.

 

(5)
In the event the Company shall propose to sell less than all the Refused Securities (any such sale to be in the manner and on
the terms specified in Section 4(m)(ii)(3) above), then the Buyer may, at its sole option and in its sole discretion, reduce the
number or amount of the Offered Securities specified in its Notice of Acceptance to an amount that shall be not less than the
number or amount of the Offered Securities that the Buyer elected to purchase pursuant to Section 4(m)(ii)(3) above multiplied
by a fraction, (i) the numerator of which shall be the number or amount of Offered Securities the Company actually proposes to
issue, sell or exchange (including Offered Securities to be issued or sold to Buyer pursuant to Section 4(m)(ii)(4) above prior
to such reduction) and (ii) the denominator of which shall be the original amount of the Offered Securities. In the event that
the Buyer so elects to reduce the number or amount of Offered Securities specified in its Notice of Acceptance, the Company may
not issue, sell or exchange more than the reduced number or amount of the Offered Securities unless and until such securities
have again been offered to the Buyer in accordance with Section 4(m)(ii)(1) above.

 

(6)
Upon the closing of the issuance, sale or exchange of all or less than all of the Refused Securities, the Buyer shall acquire
from the Company, and the Company shall issue to the Buyer, the number or amount of Offered Securities specified in the Notices
of Acceptance, as reduced pursuant to Section 4(m)(ii)(4) above if the Buyer have so elected, upon the terms and conditions specified
in the Offer. The purchase by the Buyer of any Offered Securities is subject in all cases to the preparation, execution and delivery
by the Company and the Buyer of a purchase agreement relating to such Offered Securities reasonably satisfactory in form and substance
to the Buyer and their respective counsel.

 

(7)
Any Offered Securities not acquired by the Buyer or other persons in accordance with Section 4(m)(ii)(4) above may not be issued,
sold or exchanged until they are again offered to the Buyer under the procedures specified in this Agreement.

 

    	25

    	 

    

 

(8)
The Company and the Buyer agree that if the Buyer elects to participate in the Offer, neither the Subsequent Placement Agreement
with respect to such Offer nor any other transaction documents related thereto (collectively, the “Subsequent Placement
Documents”) shall include any term or provisions whereby the Buyer shall be required to agree to any restrictions in
trading as to any securities of the Company owned by the Buyer prior to such Subsequent Placement, other than restrictions on
transfer imposed under federal and state securities laws.

 

(9)
Notwithstanding anything to the contrary in this Section 4(m) and unless otherwise agreed to by the Buyer, the Company shall either
confirm in writing to the Buyer that the transaction with respect to the Subsequent Placement has been abandoned or shall publicly
disclose its intention to issue the Offered Securities, in either case in such a manner such that the Buyer will not be in possession
of material non-public information, by the 15th Business Day following delivery of the Offer Notice. If by the 15th Business Day
following delivery of the Offer Notice no public disclosure regarding a transaction with respect to the Offered Securities has
been made, and no notice regarding the abandonment of such transaction has been received by the Buyer, such transaction shall
be deemed to have been abandoned and the Buyer shall not be deemed to be in possession of any material, non-public information
with respect to the Company. Should the Company decide to pursue such transaction with respect to the Offered Securities, the
Company shall provide the Buyer with another Offer Notice and the Buyer will again have the right of participation set forth in
this Section 4(m)(ii). From and after the Execution Date, the Company shall not be permitted to deliver more than one such Offer
Notice to the Buyer in any 60 day period.

 

(iii)
The restrictions contained in of this Section 4(m)(ii) shall not apply in connection with any Exempt Issuance.

 

(n)
Taxes. The Company will pay, and save and hold the Buyer harmless from any and all liabilities (including interest and
penalties) with respect to, or resulting from any delay or failure in paying, stamp and other taxes (other than income taxes),
if any, which may be payable or determined to be payable on the execution and delivery or acquisition of the Preferred Shares,
Warrants, Conversion Shares or Warrant Shares.

 

(o)
D&O Insurance. The Company shall obtain and thereafter maintain director’s and officer’s insurance in such
form, with such carrier and in such amounts as reasonably acceptable to the holders of a majority of the Preferred Shares (the
“D&O Insurance”) within 45 Business Days following the Closing, and, for so long as any Preferred Shares
remain outstanding.

 

(p)
Books and Records. The Company will keep proper books of record and account, in which full and correct entries shall be
made of all financial transactions and the assets and business of the Company and its Subsidiaries in accordance with GAAP.

 

(q)
Notice of Disqualification Events. The Company will notify the Buyer in writing, prior to the Closing Date of (i) any Disqualification
Event relating to any Issuer Covered Person and (ii) any event that would, with the passage of time, become a Disqualification
Event relating to any Issuer Covered Person.

 

(r)
Stock, Option and Equity Plans. From and after the Closing until the first anniversary of the Closing Date, neither the
Company nor any Subsidiary shall, without the prior written consent of the Required Holder, which consent will not be unreasonably
withheld, (i) amend or modify any economic terms or conditions of the Plan, if any, (ii) grant any stock, options or equity based
incentives to any employees, members of management, directors or advisors of, or consultants to the Company or its Subsidiaries,
other than pursuant to the Plan or agreement or arrangement, other than an Exempt Issuance, or (iii) create or implement any stock,
option or other equity incentive plan, other than the Plan, if any. .

 

(s)
Registration Rights. The Company agrees that the Buyer shall have piggyback registration rights to cause the Company to
register the Conversion Shares in each registration statement the Company files, on Forms S-1 and S-3 (or successor forms), in
accordance with a separate Registration Rights Agreement attached hereto as Exhibit E that the Parties shall execute; provided
however that the Buyer shall have no piggyback registration rights with respect to any registration statement filed in connection
with a Qualified Offering (as defined in the Certificate of Designations).

 

    	26

    	 

    

 

(t)
Distributions. While the Securities remain outstanding, the Company shall not make any distributions on equity (other than
stock dividends or stock splits in the nature of a dividend or as set forth on Schedule 4(t)), or any payments on debt other than
the scheduled payments of principal and interest, without the prior written consent of the Required Holder, as defined. Notwithstanding
the foregoing, this Section 4(t) does not apply nor will the Company require the prior written consent of the Required Holder
for the payment of cash dividends on a new series of nonconvertible preferred stock to be issued in connection with a capital
raising transaction for the purpose of uplisting the Company’s Common Stock on the Nasdaq Capital Market, NYSE American,
or any successors thereto.

 

(u)
DTC Eligibility. For so long as any Securities are outstanding, the Company will employ as the transfer agent for the Common
Stock a participant in the DTC Automated Securities Transfer Program and cause the Common Stock to be transferable pursuant to
such program.

 

(v)
Closing Documents. On or prior to 30 calendar days after the Closing Date, the Company agrees to deliver, or cause to be
delivered, to the Buyer and Nason, Yeager, Gerson, Harris & Fumero, P.A. a complete closing set of the executed Transaction
Documents, Securities and any other documents required to be delivered to any party pursuant to Section 7 hereof or otherwise.

 

5.
REGISTER.

 

The
Company shall maintain at its principal executive offices (or such other office or agency (including its transfer agent) of the
Company as it may designate by notice to each holder of Securities), a register for the Preferred Shares in which the Company
shall record the name and address of the Person in whose name the Preferred Shares have been issued (including the name and address
of each transferee), the number of Preferred Shares held by such Person and the number of Conversion Shares issuable upon conversion
of the Preferred Shares held by such Person. The Company or such other office or agency of the Company as it may designate, shall
keep the register open and available at all times during applicable business hours for inspection of the Buyer or its legal representatives.

 

6.
CONDITIONS TO THE COMPANY’S OBLIGATION TO SELL.

 

The
obligation of the Company hereunder to issue and sell the Preferred Shares and the related Warrants to the Buyer at the Closing
is subject to the satisfaction, at or before the Closing Date, of each of the following conditions, provided that these conditions
are for the Company’s sole benefit and may be waived by the Company at any time in its sole discretion by providing the
Buyer with prior written notice thereof:

 

(a)
The Buyer shall have executed this Agreement and delivered the same to the Company.

 

(b)
The Buyer shall have delivered to the Company the Initial Purchase Price for the Preferred Shares being purchased by the Buyer
at the Closing by wire transfer of immediately available funds pursuant to the wire instructions provided by the Company.

 

(c)
The representations and warranties of the Buyer shall be true and correct as of the date when made and as of the Closing Date
as though made at that time (except for representations and warranties that speak as of a specific date, which shall be true and
correct as of such specified date), and the Buyer shall have performed, satisfied and complied with the covenants, agreements
and conditions required by this Agreement to be performed, satisfied or complied with by the Buyer at or prior to the Closing
Date.

 

    	 	27	 

     

    

 

7.
CONDITIONS TO BUYER’S OBLIGATION TO PURCHASE. 

 

The
obligation of the Buyer hereunder to purchase the Preferred Shares and the related Warrants at the Closing is subject to the satisfaction,
at or before the Closing Date, of each of the following conditions, provided that these conditions are for the Buyer’s sole
benefit and may be waived by the Buyer at any time in its sole discretion by providing the Company with prior written notice thereof:

 

(a)
The Company shall have duly executed and delivered to the Buyer each of the Transaction Documents and the stock certificates representing
the Preferred Shares (allocated in such numbers as the Buyer shall request in writing at least two Business Days prior to the
Closing Date) being purchased by the Buyer at the Closing pursuant to this Agreement.

 

(b)
A Triggering Event (as defined in the Certificate of Designations) shall not have occurred prior to payment of the Subsequent
Purchase Price.

 

(c)
The Common Stock shall have been continuously quoted or listed on the Principal Market and there shall have been no intervening
suspension of trading prior to payment of the Subsequent Purchase Price. The Company shall have delivered to the Buyer a certified
copy of the Articles of Incorporation as certified by the Secretary of State of the State of Nevada within 90 days of the Closing
Date.

 

(d)
The Company shall have delivered to the Buyer a certificate, executed by the Secretary of the Company and dated as of the Closing
Date, as to (i) the resolutions consistent with Section 3(b) as adopted by the Company’s board of directors in a form reasonably
acceptable to the Buyer, (ii) the Articles of Incorporation and (iii) the Bylaws, each as in effect at the Closing, in the form
attached hereto as Exhibit C.

 

(e)
The representations and warranties of the Company shall be true and correct as of the date when made and as of the Closing Date
as though made at that time (except for representations and warranties that speak as of a specific date, which shall be true and
correct as of such specified date) and the Company shall have performed, satisfied and complied in all respects with the covenants,
agreements and conditions required by the Transaction Documents to be performed, satisfied or complied with by the Company at
or prior to the Closing Date. The Buyer shall have received a certificate, executed by the Chief Executive Officer of the Company,
dated as of the Closing Date, to the foregoing effect and as to such other matters as may be reasonably requested by the Buyer
in the form attached hereto as Exhibit D.

 

(f)
The Company shall have obtained all governmental, regulatory or third party consents and approvals, if any, necessary for the
sale of the Securities.

 

(g)
The Certificate of Designations in the form attached hereto as Exhibit A shall have been filed with the Secretary of State
of the State of Nevada and shall be in full force and effect, enforceable against the Company in accordance with its terms and
shall not have been amended.

 

(h)
The Company shall have delivered to the Buyer such other documents relating to the transactions contemplated by this Agreement
as the Buyer or its counsel may reasonably request, including without limitation a registration rights agreement executed by the
Company in the form attached as Exhibit E.

 

(i)
The Company shall have caused its counsel to furnish to the Buyer the opinion of its counsel, dated as of the Closing Date and
addressed to the Buyer in form and substance acceptable to the Buyer.

 

(j)
The Company shall have delivered to the Buyer a reservation letter to maintain the Required Reserved Amount executed by the Company’s
transfer agent and the Company in the form attached as Exhibit F.

 

8.
Reserved.

 

    	28

    	 

    

 

9.
MISCELLANEOUS.

 

(a)
Governing Law; Jurisdiction; Jury Trial. All questions concerning the construction, validity, enforcement and interpretation
of this Agreement shall be governed by the internal laws of the State of Nevada, without giving effect to any choice of law or
conflict of law provision or rule (whether of the State of Nevada or any other jurisdictions) that would cause the application
of the laws of any jurisdictions other than the State of Nevada. Each party hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in New York County, New York, for the adjudication of any dispute hereunder or in connection
herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert
in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such
suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper.
Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action
or proceeding by mailing a copy thereof to such party at the address for such notices to it under this Agreement and agrees that
such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed
to limit in any way any right to serve process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT
IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING
OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

 

(b)
Counterparts. This Agreement may be executed in two or more identical counterparts, all of which shall be considered one
and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other
party; provided that an e-mail signature shall be considered due execution and shall be binding upon the signatory thereto with
the same force and effect as if the signature were an original, not an e-mail signature.

 

(c)
Headings. The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation
of, this Agreement.

 

(d)
Severability. If any provision of this Agreement is prohibited by law or otherwise determined to be invalid or unenforceable
by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed
amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such
provision shall not affect the validity of the remaining provisions of this Agreement so long as this Agreement as so modified
continues to express, without material change, the original intentions of the parties as to the subject matter hereof and the
prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective
expectations or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise be conferred
upon the parties. The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s)
with a valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable
provision(s).

 

(e)
Entire Agreement; Amendments. This Agreement and the other Transaction Documents supersede all other prior oral or written
agreements between the Buyer, the Company, their affiliates and Persons acting on their behalf with respect to the matters discussed
herein, and this Agreement, the other Transaction Documents and the instruments referenced herein and therein contain the entire
understanding of the parties with respect to the matters covered herein and therein and, except as specifically set forth herein
or therein, neither the Company nor the Buyer makes any representation, warranty, covenant or undertaking with respect to such
matters. Provisions of this Agreement may be amended and the observance thereof may be waived (either generally or in a particular
instance and either retroactively or prospectively), only with the written consent of the Company and either (i) the holders of
at least a majority of the Preferred Shares outstanding as of the applicable date of determination, which must include Cavalry
as long as Cavalry (or any of its affiliates) owns at least five percent of the Preferred Shares issued pursuant to this Agreement,
or (ii) Cavalry as long as Cavalry (or any of its affiliates) owns at least five percent of the Preferred Shares issued pursuant
to this Agreement (the “Required Holder”); provided that any such amendment or waiver that complies with the
foregoing but that disproportionately, materially and adversely affects the rights and obligations of the Buyer relative to the
comparable rights and obligations of the other Buyer shall require the prior written consent of such adversely affected Buyer.
Any amendment or waiver effected in accordance with this Section 9(e) shall be binding upon the Buyer and holder of Securities
and the Company. No such amendment shall be effective to the extent that it applies to less than all of the Buyer or holders of
Securities. No consideration shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision
of any of the Transaction Documents unless the same consideration (other than the reimbursement of legal fees) also is offered
to all of the parties to the Transaction Documents, holders of Preferred Shares or holders of Warrants, as the case may be. The
Company has not, directly or indirectly, made any agreements with the Buyer relating to the terms or conditions of the transactions
contemplated by the Transaction Documents except as set forth in the Transaction Documents. Without limiting the foregoing, the
Company confirms that, except as set forth in this Agreement, no Buyer has made any commitment or promise or has any other obligation
to provide any financing to the Company or otherwise.

 

    	29

    	 

    

 

(f)
Notices. Any notices, consents, waivers or other communications required or permitted to be given under the terms of this
Agreement must be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon
receipt, when sent by e-mail (provided confirmation of transmission is electronically generated and kept on file by the sending
party); or (iii) one (1) Business Day after deposit with an overnight courier service, in each case properly addressed to the
party to receive the same. The addresses and email addresses for such communications shall be:

 

If
to the Company:

27
Health Holdings Corp.

Email:
jfrontiere@gmail.com

Attention:
Joseph Frontiere, CEO

 

With
a copy (for informational purposes only) to:

The
Lonergan Law Firm

Email:
llonergan@wlesq.com

Attention:
Lawrence R. Lonergan, Esq.

 

If
to the Buyer, to its address and email address set forth on its signature page,

 

With
a copy (for informational purposes only) to:

Nason,
Yeager, Gerson, Harris & Fumero, P.A.

3001
PGA Boulevard, Suite 305

Palm
Beach Gardens, FL 33410

Telephone:
561.686.3307

Email:
mharris@nasonyeager.com

Attention:
Michael D. Harris, Esq.

 

or
to such other address and/or email address and/or to the attention of such other Person as the recipient party has specified by
written notice given to each other party five days prior to the effectiveness of such change. Written confirmation of receipt
(A) given by the recipient of such notice, consent, waiver or other communication, (B) mechanically or electronically generated
by the sender’s email containing the time, date, recipient e-mail and an image of the first page of such transmission or
(C) provided by an overnight courier service shall be rebuttable evidence of personal service, receipt by e-mail or receipt from
an overnight courier service in accordance with clause (i), (ii) or (iii) above, respectively.

 

(g)
Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective
successors and assigns, including any purchasers of the Preferred Shares or the Warrants. The Company shall not assign this Agreement
or any rights or obligations hereunder without the prior written consent of the Required Holder, including by way of a Fundamental
Transaction (unless the Company is in compliance with the applicable provisions governing Fundamental Transactions set forth in
the Certificate of Designations and the Warrants). The Buyer may assign some or all of its rights hereunder without the consent
of the Company, in which event such assignee shall be deemed to be the Buyer hereunder with respect to such assigned rights.

 

(h)
No Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted
successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except that
each Indemnitee shall have the right to enforce the obligations of the Company with respect to Section 9(k).

 

    	30

    	 

    

 

(i)
Survival. Unless this Agreement is terminated under Section 8, the representations, warranties, agreements and covenants
hereunder shall survive the Closing and the delivery, conversion and/or exercise of the Securities, as applicable. The Buyer shall
be responsible only for its own representations, warranties, agreements and covenants hereunder.

 

(j)
Further Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things,
and shall execute and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably
request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions
contemplated hereby.

 

(k)
Indemnification.

 

(i)
In consideration of the Buyer’s execution and delivery of the Transaction Documents and acquiring the Securities thereunder
and in addition to all of the Company’s other obligations under the Transaction Documents, the Company shall defend, protect,
indemnify and hold harmless the Buyer and each other holder of the Securities and all of their stockholders, partners, members,
officers, directors, employees and direct or indirect Buyers and any of the foregoing Persons’ agents or other representatives
(including, without limitation, those retained in connection with the transactions contemplated by this Agreement) (collectively,
the “Indemnitees”) from and against any and all actions, causes of action, suits, claims, losses, costs, penalties,
fees, liabilities and damages, and expenses in connection therewith (irrespective of whether any such Indemnitee is a party to
the action for which indemnification hereunder is sought), and including reasonable attorneys’ fees and disbursements (the
“Indemnified Liabilities”), incurred by any Indemnitee as a result of, or arising out of, or relating to (a)
any misrepresentation or breach of any representation or warranty made by the Company in the Transaction Documents or any other
certificate, instrument or document contemplated hereby or thereby, (b) any breach of any covenant, agreement or obligation of
the Company contained in the Transaction Documents or any other certificate, instrument or document contemplated hereby or thereby
or (c) any cause of action, suit or claim brought or made against such Indemnitee by a third party (including for these purposes
a derivative action brought on behalf of the Company) and arising out of or resulting from (i) the execution, delivery, performance
or enforcement of the Transaction Documents or any other certificate, instrument or document contemplated hereby or thereby, (ii)
any transaction financed or to be financed in whole or in part, directly or indirectly, with the proceeds of the issuance of the
Securities, (iii) any disclosure made by the Buyer pursuant to Section 4(h), or (iv) the status of the Buyer or holder of the
Securities as an Buyer in the Company pursuant to the transactions contemplated by the Transaction Documents. To the extent that
the foregoing undertaking by the Company may be unenforceable for any reason, the Company shall make the maximum contribution
to the payment and satisfaction of each of the Indemnified Liabilities that is permissible under applicable law.

 

(ii)
Promptly after receipt by an Indemnitee under this Section 9(k) of notice of the commencement of any action or proceeding (including
any governmental action or proceeding) involving an Indemnified Liability, such Indemnitee shall, if a claim for indemnification
in respect thereof is to be made against any indemnifying party under this Section 9(k), deliver to the indemnifying party a written
notice of the commencement thereof, and the indemnifying party shall have the right to participate in, and, to the extent the
indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume control of the defense thereof
with counsel mutually satisfactory to the indemnifying party and the Indemnitee; provided, however, that an Indemnitee shall have
the right to retain its own counsel with the fees and expenses of not more than one counsel for such Indemnitee to be paid by
the indemnifying party, if, in the reasonable opinion of counsel selected to defend the Indemnitee, the representation by such
counsel of the Indemnitee and the indemnifying party would be inappropriate due to actual or potential differing interests between
such Indemnitee and any other party represented by such counsel in such proceeding. Legal counsel referred to in the immediately
preceding sentence shall be selected by the Buyers holding at least a majority of the Purchased Shares. The Indemnitee shall cooperate
fully with the indemnifying party in connection with any negotiation or defense of any such action or Indemnified Liabilities
by the indemnifying party and shall furnish to the indemnifying party all information reasonably available to the Indemnitee that
relates to such action or Indemnified Liabilities. The indemnifying party shall keep the Indemnitee fully apprised at all times
as to the status of the defense or any settlement negotiations with respect thereto. No indemnifying party shall be liable for
any settlement of any action, claim or proceeding effected without its prior written consent, provided, however, that the indemnifying
party shall not unreasonably withhold, delay or condition its consent. No indemnifying party shall, without the prior written
consent of the Indemnitee, which consent shall not be unreasonably withheld conditioned or delayed, consent to entry of any judgment
or enter into any settlement or other compromise which does not include as an unconditional term thereof the giving by the claimant
or plaintiff to such Indemnitee of a release from all liability in respect to such Indemnified Liabilities or litigation. Following
indemnification as provided for hereunder, the indemnifying party shall be subrogated to all rights of the Indemnitee with respect
to all third parties, firms or corporations relating to the matter for which indemnification has been made. No Indemnitee shall
enter into any settlement of any action or proceeding subject to this Section 9(k) without the prior written consent of the indemnifying
party. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such
action shall not relieve such indemnifying party of any liability to the Indemnitee under this Section 9(k), except to the extent
that the indemnifying party is prejudiced in its ability to defend such action.

 

    	31

    	 

    

 

(iii)
The indemnification required by this Section 9(k) shall be made by periodic payments of the amount thereof during the course of
the investigation or defense, as and when bills are received or Indemnified Liabilities are incurred.

 

(iv)
The indemnity agreements contained herein shall be in addition to (x) any cause of action or similar right of the Indemnitee against
the indemnifying party or others, and (y) any liabilities the indemnifying party may be subject to pursuant to the law.

 

(l)
No Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to
express their mutual intent, and no rules of strict construction will be applied against any party.

 

(m)
Remedies. The Buyer and each holder of the Securities shall have all rights and remedies set forth in the Transaction Documents
and all rights and remedies which such holders have been granted at any time under any other agreement or contract and all of
the rights which such holders have under any law. Any Person having any rights under any provision of this Agreement shall be
entitled to enforce such rights specifically to recover damages by reason of any breach of any provision of this Agreement and
to exercise all other rights granted by law. Furthermore, the Company recognizes that in the event that it fails to perform, observe,
or discharge any or all of its obligations under the Transaction Documents, any remedy at law may prove to be inadequate relief
to the Buyer. The Company therefore agrees that the Buyer shall be entitled to seek temporary and permanent injunctive relief
in any such case without the necessity of proving actual damages.

 

(n)
Rescission and Withdrawal Right. Notwithstanding anything to the contrary contained in (and without limiting any similar
provisions of) the Transaction Documents, whenever the Buyer exercises a right, election, demand or option under a Transaction
Document and the Company does not timely perform its related obligations within the periods therein provided, then the Buyer may
rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand
or election in whole or in part without prejudice to its future actions and rights.

 

(o)
Payment Set Aside. To the extent that the Company makes a payment or payments to the Buyer hereunder or pursuant to any
of the other Transaction Documents or the Buyer enforce or exercise their rights hereunder or thereunder, and such payment or
payments or the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent
or preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company,
a trustee, receiver or any other Person under any law (including, without limitation, any bankruptcy law, foreign, state or federal
law, common law or equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally
intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such
enforcement or setoff had not occurred.

 

(p)
Reproduction of Documents. This Agreement and all documents relating thereto, including, without limitation, (a) consents,
waivers and modifications which may hereafter be executed, (b) documents received by the Buyer on the Closing Date (except for
certificates evidencing the Preferred Shares themselves), and (c) financial statements, certificates and other information previously
or hereafter furnished to the Buyer, may be reproduced by the Buyer by any photographic, photostatic, microfilm, micro-card, miniature
photographic or other similar process and the Buyer may destroy any original document so reproduced. All parties hereto agree
and stipulate that any such reproduction shall be admissible in evidence as the original itself in any judicial or administrative
proceeding (whether or not the original is in existence and whether or not such reproduction was made by the Buyer in the regular
course of business) and that any enlargement, facsimile or further reproduction of such reproduction shall likewise be admissible
in evidence.

 

    	32

    	 

    

 

(q)
Independent Nature of Buyer’ Obligations and Rights. The obligations of the Buyer under any Transaction Document
are several and not joint with the obligations of any other Buyer, and no Buyer shall be responsible in any way for the performance
of the obligations of any other Buyer under any Transaction Document. Nothing contained herein or in any other Transaction Document,
and no action taken by the Buyer pursuant hereto or thereto, shall be deemed to constitute the Buyer as, and the Company acknowledges
that the Buyer do not so constitute, a partnership, an association, a joint venture or any other kind of entity, or create a presumption
that the Buyer are in any way acting in concert or as a group, and the Company shall not assert any such claim with respect to
such obligations or the transactions contemplated by the Transaction Documents and the Company acknowledges that the Buyer are
not acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents.
The Company acknowledges and the Buyer confirms that it has independently participated in the negotiation of the transaction contemplated
hereby with the advice of its own counsel and advisors. The Buyer shall be entitled to independently protect and enforce its rights,
including, without limitation, the rights arising out of this Agreement or out of any other Transaction Documents, and it shall
not be necessary for any other Buyer to be joined as an additional party in any proceeding for such purpose.

 

(r)
Knowledge Definition. “Knowledge”, “Knowledge of Company” or “Company’s
Knowledge” or any other similar knowledge qualification, means the actual or constructive knowledge of Joseph Frontiere
after due inquiry in his capacity as the Chief Executive Officer of the Company and the Chief Financial Officer of the Company
after due inquiry in his capacity as the Chief Financial Officer.

 

(s)
Transaction Expenses. The Company shall pay the Buyer’s legal fees and expenses incurred in connection with this
Agreement and the transactions contemplated hereby, for an amount of $30,000, which may be withheld from the Initial Purchase
Price by the Buyer.

 

    	33

    	 

    

 

IN
WITNESS WHEREOF, the Buyer and the Company have caused their respective signature page to this Securities Purchase Agreement
to be duly executed as of the Execution Date.

 

	COMPANY:	 
	 	 
	27 Health Holdings Corp. 	 
	 	 
	By:	 	 
	Name:	Joseph Frontiere	 
	Title:	Chief Executive Officer	 

 

IN
WITNESS WHEREOF, the Buyer and the Company have caused their respective signature page to this Securities Purchase Agreement
to be duly executed as of the Execution Date.

 

	BUYER:	 
	 	 
	CAVALRY FUND I LP	 
	 	 
	By:	        	 
	Name: 	 	 
	Title:	 	 

 

	 	Preferred Shares:	450
	 	Warrants:	450,000

 

    	34Exhibit
10.4 

 

NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO,
THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A
LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.
THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN
ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

COMMON
STOCK PURCHASE WARRANT

27
Health Holdings Corp.

 

	Warrant
    Shares: 450,000	Initial
    Exercise Date: July 30, 2020

 

THIS
COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Cavalry Fund I LLP, or its
assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions
hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior
to the close of business on the five year anniversary of the Initial Exercise Date (the “Termination Date”)
but not thereafter, to subscribe for and purchase from 27 Health Holdings Corp., a Nevada corporation (the “Company”),
up to 450,000 shares of Common Stock (subject to adjustment hereunder, the “Warrant Shares”). The purchase
price of one Warrant Share shall be equal to the Exercise Price (defined below).

 

Section
1. Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain
Securities Purchase Agreement (the “Purchase Agreement”), dated July 30, 2020, among the Company and the Buyer
listed on the signature page.

 

Section
2. Exercise.

 

(a)
As of the Initial Exercise Date, a total of 278,000 shares of Common Stock may be purchased, subject to adjustment, and if the
Subsequent Purchase, as defined in the Purchase Agreement, occurs, the remaining 172,000 shares of Common Stock may be purchased,
subject to adjustment. Subject to the prior sentence of this Section 2(a), exercise of the purchase rights represented by this
Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination
Date by delivery to the Company (or such other office or agency of the Company as it may designate by notice in writing to the
registered Holder at the address of the Holder appearing on the books of the Company) of a duly executed facsimile copy of the
“Notice of Exercise Form” annexed hereto. Within two Trading Days following the date of exercise as aforesaid, the
Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer
or cashier’s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below
is specified in the applicable Notice of Exercise. Notwithstanding anything herein to the contrary (although the Holder may surrender
the Warrant to, and receive a replacement Warrant from, the Company), the Holder shall not be required to physically surrender
this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been
exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading
Days of the date the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases
of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number
of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and
the Company and its Transfer Agent shall maintain records showing the number of Warrant Shares purchased and the date of such
purchases. The Company shall deliver any objection to any Notice of Exercise Form within one Trading Day of delivery of such notice.
The Holder by acceptance of this Warrant, acknowledges and agrees that, by reason of the provisions of this paragraph, following
the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any
given time may be less than the amount stated on the face hereof.

 

    	 

    	 

    

 

(b)
Exercise Price. The exercise price per share of the Common Stock under this Warrant shall be equal to $1.10 per share,
subject to adjustment under Section 3 (the “Exercise Price”).

 

(c)
Cashless Exercise. Beginning six months after the Initial Exercise Date if there is no effective registration statement
covering the resale of the Warrant Shares by the Holder or the prospectus does not comply with Section 5(b) of the 1933 Act, then
this Warrant may also be exercised at the Holder’s election, in whole or in part and in lieu of making the cash payment
otherwise contemplated to be made to the Company upon such exercise, at such time by means of a “cashless exercise”
in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A x B)
– (A x C)] by (D), where:

 

(A)
= the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant
if such exercise were by means of a cash exercise rather than a cashless exercise;

 

(B)
= the greater of (i) the arithmetic average of the VWAPs (as defined below) for the five consecutive Trading Days ending on the
date immediately preceding the date on which the Holder elects to exercise this Warrant by means of a “cashless exercise,”
as set forth in the applicable Notice of Exercise or (ii) the VWAP for the Trading Day immediately prior to the date on which
the Holder makes such “cashless exercise” election;

 

(C)
= the Exercise Price of this Warrant, as adjusted hereunder, at the time of such exercise; and

 

(D)
= the lesser of (i) the arithmetic average of the VWAPs for the five consecutive Trading Days ending on the date immediately preceding
the date on which the Holder elects to exercise this Warrant by means of a “cashless exercise,” as set forth in the
applicable Notice of Exercise or (ii) the VWAP for the Trading Day immediately prior to the date on which the Holder makes such
“cashless exercise” election.

 

“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Principal Market upon
which the Common Stock is then listed or quoted is a trading market, the daily volume weighted average price of the Common Stock
for such date (or the nearest preceding date) on the Principal Market as reported by Bloomberg L.P. (based on a Trading Day from
9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the Principal Market upon which the Common Stock is
then listed or quoted is not a trading market, the volume weighted average price of the Common Stock for such date (or the nearest
preceding date) on such Principal Market as applicable, (c) if the Common Stock is not then listed or quoted on the Principal
Market, and if prices for the Common Stock are then reported in the OTC Pink Marketplace of OTC Markets Group, Inc., the most
recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common
Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities
then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

 

If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9)
of the 1933 Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding period
of the Warrants being exercised may be tacked on to the holding period of the Warrant Shares. The Company agrees not to take any
position contrary to this Section 2(c).

 

Notwithstanding
anything herein to the contrary, if on the Termination Date (unless the Holder notifies the Company otherwise) if there is no
effective registration statement covering the resale of the Warrant Shares by the Holder, then this Warrant shall be automatically
exercised via cashless exercise pursuant to this Section 2(c).

 

    	 	2	 

     

    

 

(d)
Mechanics of Exercise.

 

(i)
Delivery of Certificates Upon Exercise. Certificates for shares purchased hereunder shall be transmitted to the Holder
by the Transfer Agent to the Holder by crediting the account of the Holder’s prime broker with The Depository Trust Company
through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company is then a participant in such
system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale
of the Warrant Shares by the Holder or (B) this Warrant is being exercised via cashless exercise and Rule 144 is available, and
otherwise by physical delivery to the address specified by the Holder in the Notice of Exercise by the date that is three Trading
Days after the latest of (A) the delivery to the Company of the Notice of Exercise and (B) payment of the aggregate Exercise Price
as set forth above (unless by cashless exercise, if permitted) (such date, the “Warrant Share Delivery Date”).
The Warrant Shares shall be deemed to have been issued, and Holder or any other person so designated to be named therein shall
be deemed to have become a holder of record of such shares for all purposes, as of the date the Warrant has been exercised, with
payment to the Company of the Exercise Price (or by cashless exercise, if permitted) and all taxes required to be paid by the
Holder, if any, pursuant to Section 2(d)(vi) prior to the issuance of such shares, having been paid. The Company understands that
a delay in the delivery of the Warrant Shares after the Warrant Share Delivery Date (defined for the purposes of this Warrant
as 72 hours from receipt of notice of exercise by the Company and its Transfer Agent) could result in economic loss to the Holder.
As compensation to the Holder for such loss, the Company agrees to pay (as liquidated damages and not as a penalty) to the Holder
for late issuance of Warrant Shares upon exercise of this Warrant the proportionate amount of $5 per Trading Day (increasing to
$10 per Trading Day after the fifth Trading Day) after the Warrant Share Delivery Date for each $1,000 of Exercise Price of Warrant
Shares for which this Warrant is exercised which are not timely delivered. In no event shall liquidated damages for any one transaction
exceed $1,000.00 for the first 10 Trading Days. The Company shall pay any payments incurred under this Section 2(d)(i) in immediately
available funds upon demand. Furthermore, in addition to any other remedies which may be available to the Holder, in the event
that the Company fails for any reason to effect delivery of the Warrant Shares by the Warrant Share Delivery Date, the Holder
may revoke all or part of the relevant Warrant exercise by delivery of a notice to such effect to the Company, whereupon the Company
and the Holder shall each be restored to their respective positions immediately prior to the exercise of the relevant portion
of this Warrant, except that the liquidated damages described above shall be payable through the date notice of revocation or
rescission is given to the Company.

 

(ii)
Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request
of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the certificate or certificates representing
Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares
called for by this Warrant, which new Warrant shall in all other respects be identical to this Warrant.

 

(iii)
Rescission Rights. If the Company fails to deliver the Warrant Shares by crediting the account of the Holder’s prime
broker via DWAC and causes the Transfer Agent to transmit to the Holder a certificate or the certificates representing the Warrant
Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right, at any time prior
to issuance of such Warrant Shares, to rescind such exercise.

 

(iv)
Compensation for Buy-In on Failure to Timely Deliver Certificates Upon Exercise. In addition to any other rights available
to the Holder, if the Company fails to deliver the Warrant Shares, or cause the Transfer Agent to transmit to the Holder a certificate
or the certificates representing the Warrant Shares pursuant to an exercise on or before the Warrant Share Delivery Date, and
if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder’s
brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares
which the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company shall (A) pay in cash
to the Holder the amount, if any, by which (x) the Holder’s total purchase price (including brokerage commissions, if any)
for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that
the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell
order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion
of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall
be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company
timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having
a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate
sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company
shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall
limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation,
a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver certificates
representing shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.

 

    	 	3	 

     

    

 

(v)
No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the
Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction
multiplied by the Exercise Price or round up to the next whole share.

 

(vi)
Charges, Taxes and Expenses. Issuance of certificates for Warrant Shares shall be made without charge to the Holder for
any issue or transfer tax or other incidental expense in respect of the issuance of such certificate including any charges of
any clearing firm, all of which taxes and expenses shall be paid by the Company, and such certificates shall be issued in the
name of the Holder or in such name or names as may be directed by the Holder; provided, however, that in the event
certificates for Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require,
as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall
pay all Transfer Agent fees required for same-day processing of any Notice of Exercise.

 

(vii)
Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.

 

(e)
Holder’s Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not
have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect
to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s
affiliates, and any other Persons acting as a group together with the Holder or any of the Holder’s affiliates), would beneficially
own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of
shares of Common Stock beneficially owned by the Holder and its affiliates shall include the number of shares of Common Stock
issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of
shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially
owned by the Holder or any of its affiliates and (ii) exercise or conversion of the unexercised or nonconverted portion of any
other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on
conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its affiliates.
Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in
accordance with Section 13(d) of the 1934 Act and the rules and regulations promulgated thereunder, it being acknowledged by the
Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the 1934
Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the
limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other
securities owned by the Holder together with any affiliates) and of which portion of this Warrant is exercisable shall be in the
sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any affiliates) and
of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company
shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group
status as contemplated above shall be determined in accordance with Section 13(d) of the 1934 Act and the rules and regulations
promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock,
a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic
or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a
more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.
Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder
the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be
determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder
or its affiliates since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial
Ownership Limitation” shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving
effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon not less than 61 days’
prior notice to the Company, may increase the Beneficial Ownership Limitation provisions of this Section 2(e) solely with respect
to the Holder’s Warrant, provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares
of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant
held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any such increase will not be effective until
the 61st day after such notice is delivered to the Company. The Holder may also decrease the Beneficial Ownership Limitation
provisions of this Section 2(e) solely with respect to the Holder’s Warrant at any time, which decrease shall be effectively
immediately upon delivery of notice to the Company. The provisions of this paragraph shall be construed and implemented in a manner
otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which
may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements
necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to
a successor holder of this Warrant.

 

    	 	4	 

     

    

 

(f)
Automatic Exercise. 

 

(i)
Notwithstanding anything herein to the contrary, if at any time (i) the closing price of the Common Stock on the principal Trading
Market is at least $3.00 per share for 10 consecutive Trading Days, (ii) the average of the daily trading dollar volume of the
Common Stock during that same period is at least $150,000 per day, and (iii) the Warrant Shares are registered pursuant to an
effective registration statement and the prospectus complies with Section 5(b) of the 1933 Act, the remainder of this Warrant
shall be automatically exercised in full, and, the Holder shall, within 30 Trading Days after its receipt of written notice from
the Company that the foregoing conditions have been met, deliver the Exercise Price to the Company or exercise the Warrant by
means of a cashless exercise, and the Company shall cause its Transfer Agent to deliver the remaining Warrant Shares to the Holder
within 72 hours, in accordance with the procedures set forth in Section 2; provided, however, that this Section
2(f) shall only apply if as of the applicable date no Equity Conditions Failure has occurred. 

 

(ii)
For the purposes of this Section 2(f), “Equity
Conditions Failure” means that any of the Equity Conditions was not satisfied at all times during an applicable Equity
Conditions Measuring Period. “Equity Conditions” means, except as otherwise provided, on each day during the
period beginning one month prior to the applicable date of determination and ending on such applicable date of determination (the
“Equity Conditions Measuring Period”), (a) the Common Stock is listed or designated for quotation (as applicable)
on a Principal Market and shall not have been suspended from trading on any such Principal Market, nor shall delisting or suspension
by a Principal Market have been threatened or be reasonably likely to occur as evidenced by (A) a writing by such Principal Market
or (B) the Company or its Common Stock falling below the minimum listing maintenance requirements of the Principal Market on which
the Common Stock is then listed or designated for quotation (as applicable); (b) the Company shall have delivered all shares of
Common Stock issuable upon exercise of this Warrant and each other Transaction Document on a timely basis as provided in this
Warrant; (c) any shares of Common Stock to be issued in connection with the provisions of any Transaction Document may be issued
in full without violating the rules or regulations of the Principal Market on which the Common Stock is then listed or designated
for quotation (as applicable); (d) no public announcement of a pending, proposed or intended Fundamental Transaction shall have
occurred which has not been abandoned, terminated or consummated; (e) there has not been a suspension from trading or the failure
of the Common Stock to be trading or listed (as applicable) on a Principal Market for a period of five consecutive Trading Days;
(f) there has been no occurrence of or continuation of any default under, prepayment of or acceleration prior to maturity of an
aggregate of $25,000 or more of Indebtedness of the Company or any of its Subsidiaries; (g) the Company otherwise shall have been
in material compliance with each, and shall not have breached any, term, provision, covenant, representation or warranty of any
Transaction Document; (h) a Triggering Event (as defined in the Certificate of Designations) has not existed; (i) since the date
the holder received notice of automatic exercise under Section 2(f) the Holder shall not be in possession of any material, non-public
information provided to it by the Company, any of its Subsidiaries or any of their respective affiliates, employees, officers,
directors, shareholders, members, managers, partners, representatives or agents; (j) on the applicable date of determination (1)
no failure on the part of the Company to maintain shares of Common Stock authorized and reserved for issuance sufficient to meet
the Required Reserved Amount shall exist or be continuing, (2) the number of shares of Common Stock available under the articles
of incorporation of the Company and reserved by the Company to be issued pursuant to the Preferred Shares and Warrants shall be
greater than the Required Reserve Amount, and (3) all shares of Common Stock to be issued in connection with the event requiring
this determination may be issued in full without resulting in a failure described in (1); (k) no bona fide dispute shall exist,
by and between the Holder of the Warrants or Preferred Shares, the Company, a Principal Market and/or the Financial Industry Regulatory
Authority with respect to any term or provision of any Warrant or any other Transaction Document, and (l) the shares of Common
Stock issuable pursuant the event requiring the satisfaction of the Equity Conditions (without regard to any limitations on exercise
set forth herein) are duly authorized and listed, if required, and eligible for trading without restriction on a Principal Market.

 

    	 	5	 

     

    

 

Section
3. Certain Adjustments.

 

(a)
Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or
otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities
payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company
upon exercise of this Warrant or pursuant to any of the other Transaction Documents), (ii) subdivides outstanding shares of Common
Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock
into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock
of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number
of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator
shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon
exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain
unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the
determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.

 

(b)
Adjustments for Issuance of Additional Securities. For a period of two years from the Initial Exercise Date, in the event
that the Company shall, at any time, effect a Subsequent Placement (in a transaction other than in connection with the issuance
of any Excluded Securities), at a price per share less than the Exercise Price then in effect or without consideration (a “Dilutive
Issuance” based on a “Dilutive Issuance Price”), then the Exercise Price upon each such issuance
shall be reduced to the Dilutive Issuance Price, and the number of Warrant Shares (excluding Warrant Shares previously exercised)
shall be increased on a full ratchet basis to the number of shares of Common Stock determined by multiplying the Exercise Price
then in effect immediately prior to such adjustment by the number of Warrant Shares (excluding Warrant Shares previously exercised)
acquirable upon exercise of this Warrant immediately prior to such adjustment and dividing the product thereof by the Exercise
Price resulting from such adjustment. By way of example, if E is the total number of Warrant Shares in effect immediately prior
to such Dilutive Issuance, F is the Exercise Price in effect immediately prior to such Dilutive Issuance, and G is the Dilutive
Issuance Price, the adjustment to the number of Warrant Shares can be expressed in the following formula: Total number of Warrant
Shares after such Dilutive Issuance = the quotient obtained from dividing [E x F] by G.

 

(c)
Change in Option Price or Rate of Conversion. If the price per share for which shares of Common Stock may be issuable pursuant
to any Common Stock Equivalent, is less than the applicable Exercise Price then in effect, or if, after any such issuance of Common
Stock Equivalents, the price per share for which shares of Common Stock may be issuable thereafter is amended or adjusted, and
such price as so amended shall be less than the applicable Exercise Price in effect at the time of such amendment or adjustment,
then the applicable Exercise Price and number of Warrant Shares shall be adjusted upon each such issuance or amendment as provided
in this Section 3(c).

 

(d)
Calculation of Consideration Received. In case any Common Stock Equivalent is issued in connection with the issue or sale
of other securities of the Company, together comprising one integrated transaction, (x) the Common Stock Equivalents will be deemed
to have been issued for the Option Value of such Common Stock Equivalents and (y) the other securities issued or sold in such
integrated transaction shall be deemed to have been issued or sold for the difference of (I) the aggregate consideration received
by the Company less any consideration paid or payable by the Company pursuant to the terms of such other securities of the Company,
less (II) the Option Value. If any shares of Common Stock or Common Stock Equivalents are issued or sold or deemed to have been
issued or sold for cash, the amount of such consideration received by the Company will be deemed to be the net amount received
by the Company therefor. If any shares of Common Stock or Common Stock Equivalents are issued or sold for a consideration other
than cash, the amount of such consideration received by the Company will be the fair value of such consideration, except where
such consideration consists of publicly traded securities, in which case the amount of consideration received by the Company will
be the VWAP of such public traded securities on the date of receipt. If any shares of Common Stock or Common Stock Equivalents
are issued to the owners of the non-surviving entity in connection with any merger in which the Company is the surviving entity,
the amount of consideration therefor will be deemed to be the fair value of such portion of the net assets and business of the
non-surviving entity as is attributable to such shares of Common Stock or Common Stock Equivalents, as the case may be.

 

    	 	6	 

     

    

 

“Option
Value” means the value of a Common Stock Equivalent based on the Black Scholes Option Pricing model obtained from the
“OV” function on Bloomberg L.P. determined as of (A) the Trading Day prior to the public announcement of the issuance
of the applicable Common Stock Equivalent, if the issuance of such Common Stock Equivalent is publicly announced or (B) the Trading
Day immediately following the issuance of the applicable Common Stock Equivalent if the issuance of such Common Stock Equivalent
is not publicly announced, for pricing purposes and reflecting (i) a risk-free interest rate corresponding to the U.S. Treasury
rate for a period equal to the remaining term of the applicable Common Stock Equivalent as of the applicable date of determination,
(ii) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg
L.P. as of (A) the Trading Day immediately following the public announcement of the applicable Common Stock Equivalent if the
issuance of such Common Stock Equivalent is publicly announced or (B) the Trading Day immediately following the issuance of the
applicable Common Stock Equivalent if the issuance of such Common Stock Equivalent is not publicly announced, (iii) the underlying
price per share used in such calculation shall be the highest VWAP of the Common Stock during the period beginning on the Trading
Day prior to the execution of definitive documentation relating to the issuance of the applicable Common Stock Equivalent and
ending on (A) the Trading Day immediately following the public announcement of such issuance, if the issuance of such Common Stock
Equivalent is publicly announced or (B) the Trading Day immediately following the issuance of the applicable Common Stock Equivalent
if the issuance of such Common Stock Equivalent is not publicly announced, (iv) a zero cost of borrow and (v) a 360 day annualization
factor.

 

The
provisions of this Section 3(e) shall apply each time the Company, at any time after the Initial Exercise Date and prior to the
date that is two years from the Initial Exercise Date, shall issue any securities with a Dilutive Issuance Price. Notwithstanding
the foregoing, no adjustment shall be made pursuant to this Section 3(e) with respect to an Exempt Issuance (as defined in the
Purchase Agreement).

 

(e)
Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above and any rights contained in
the Purchase Agreement, for a period of two years from the Initial Exercise Date, if the Company grants, issues or sells any Common
Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class
of shares of Common Stock (the “Purchase Rights”), then the Holder will be entitled to acquire, upon the terms
applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held
the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken
for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders
of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, to the
extent that the Holder’s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial
ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent
shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding
the Beneficial Ownership Limitation).

 

(f)
Pro Rata Distributions. If the Company, for a period of two (2) years from the Initial Exercise Date, shall distribute
to all holders of Common Stock (and not to the Holder) evidences of its indebtedness or assets (including cash and cash dividends)
or rights or warrants to subscribe for or purchase any security other than the Common Stock, then in each such case the Exercise
Price shall be adjusted by multiplying the Exercise Price in effect immediately prior to the record date fixed for determination
of stockholders entitled to receive such distribution by a fraction of which the denominator shall be the VWAP determined as of
the record date mentioned above, and of which the numerator shall be such VWAP on such record date less the then per share fair
market value at such record date of the portion of such assets or evidence of indebtedness so distributed applicable to one outstanding
share of the Common Stock as determined by the Board of Directors in good faith. In either case the adjustments shall be described
in a statement provided to the Holder of the portion of assets or evidences of indebtedness so distributed or such subscription
rights applicable to one share of Common Stock. Such adjustment shall be made whenever any such distribution is made and shall
become effective immediately after the record date mentioned above.

 

    	 	7	 

     

    

 

(g)
Fundamental Transaction. For a period of two years from the Initial Exercise Date, if (i) the Company, directly or indirectly,
in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell,
tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of
the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification,
reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is
effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in
one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without
limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person or group of Persons whereby
such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common
Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making
or party to, such stock or share purchase agreement or other business combination) (each a “Fundamental Transaction”),
then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would
have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction (without regard to any
limitation on the exercise of this Warrant), at the option of the Holder the number of shares of Common Stock of the successor
or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the “Alternate
Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common
Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation
on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately
adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share
of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration
in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of
Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the
Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following
such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company
or any Successor Entity (as defined below) shall, at the Holder’s option, exercisable at any time concurrently with, or
within 30 days after, the consummation of the Fundamental Transaction, purchase this Warrant from the Holder by paying to the
Holder an amount of cash equal to (i) the Black Scholes Value of the remaining unexercised portion of this Warrant on the date
of the consummation of such Fundamental Transaction or (ii) the positive difference between the cash per share paid in such Fundamental
Transaction minus the then in effect Exercise Price. “Black Scholes Value” means the value of the unexercised portion
of this Warrant based on the Black and Scholes Option Pricing Model obtained from the “OV” function on Bloomberg L.P.
determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free
interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement
of the applicable Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the greater of 100% and
the 100 day volatility obtained from the HVT function on Bloomberg L.P. as of the Trading Day immediately following the public
announcement of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the
sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered
in such Fundamental Transaction and (D) a remaining option time equal to the time between the date of the public announcement
of the applicable Fundamental Transaction and the Termination Date. The Company shall cause any successor entity in a Fundamental
Transaction in which the Company is not the survivor (the “Successor Entity”) to assume in writing all of the
obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section
3(g) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without
unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange
for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance
to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent
entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant prior to such Fundamental
Transaction (without regard to any limitation on the exercise of this Warrant), and with an exercise price which applies the exercise
price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant
to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such
exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of
such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of
any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date
of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the “Company”
shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the
obligations of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity
had been named as the Company herein. Notwithstanding the foregoing, no adjustment shall be made pursuant to this Section 3(g)
with respect to an Exempt Issuance (as defined in the Purchase Agreement).

 

    	 	8	 

     

    

 

(h)
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of
a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding
as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

(i)
Notice to Holder.

 

(i)
Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the
Company shall promptly email to the Holder a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment. The Holder may supply
an email address to the Company and change such address.

 

(ii)
Notice to Allow Exercise by Holder. For a period of two years from the Initial Exercise Date, if (A) the Company shall
declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring
cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common
Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval
of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation
or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any
compulsory share exchange whereby the Common Stock is converted into other securities, or (E) the Company shall authorize the
voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company
shall deliver to the Holder at its last address as it shall appear upon the Warrant Register (as defined below) of the Company,
at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date
on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record
is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions,
redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale,
transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the
Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable
upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to email such notice
or any defect therein or in the emailing thereof shall not affect the validity of the corporate action required to be specified
in such notice. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding
the Company or any of the Subsidiaries (as determined in good faith by the Company), the Company shall simultaneously file such
notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant
during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may
otherwise be expressly set forth herein.

 

    	 	9	 

     

    

 

Section
4. Transfer of Warrant.

 

(a)
Transferability. Subject to compliance with any applicable securities laws and the provisions of the Purchase Agreement,
this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in
part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment
of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient
to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company
shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination
or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion
of this Warrant not so assigned, and this Warrant shall promptly be cancelled. The Warrant, if properly assigned in accordance
herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.

 

(b)
New Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office
of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued,
signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved
in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or
Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated
the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable
pursuant thereto.

 

(c)
Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose
(the “Warrant Register”) and/or cause its Transfer Agent register this Warrant, upon records to be maintained
by the Transfer Agent, in the name of the record Holder hereof from time to time. The Company and its Transfer Agent may deem
and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution
to the Holder, and for all other purposes, absent actual notice to the contrary.

 

(d)
Representation of the Holder. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant
and, upon any exercise hereof, will acquire the Warrant Shares issuable upon exercise, for its own account and not with a view
to or for distributing or reselling such Warrant Shares or any part thereof in violation of the 1933 Act or any applicable state
securities law, except pursuant to sales registered or exempted under the 1933 Act.

 

Section
5. Miscellaneous.

 

(a)
No Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or other
rights as a stockholder of the Company prior to the exercise hereof other than as explicitly set forth in Section 3.

 

(b)
Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it, and upon surrender
and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock
certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.

 

(c)
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next
succeeding Trading Day.

 

    	 	10	 

     

    

 

(d)
Authorized Shares. The Company covenants that during the period the Warrant is outstanding, it will maintain the Required
Reserved Amount as set forth in Section 4(k) of the Purchase Agreement. The Company further covenants that its issuance of this
Warrant shall constitute full authority to its officers who are charged with the duty of executing stock certificates to execute
and issue the necessary certificates for the Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company
will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without
violation of any applicable law or regulation, or of any requirements of any Trading Market upon which the Common Stock may be
listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented
by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in
accordance herewith, be duly authorized, validly issued, fully paid and non-assessable and free from all taxes, liens and charges
created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously
with such issue).

 

Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation,
amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution,
issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the
terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all
such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment.
Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above
the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may
be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares
upon the exercise of this Warrant and (iii) use best efforts to obtain all such authorizations, exemptions or consents from any
public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under
this Warrant.

 

Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or
in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be
necessary from any public regulatory body or bodies having jurisdiction thereof.

 

(e)
Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall
be determined in accordance with the provisions of the Purchase Agreement.

 

(f)
Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered
or if not exercised on a cashless basis when Rule 144 and/or Section 4(a)(1) of the 1933 Act are available, may have restrictions
upon resale imposed by state and federal securities laws.

 

(g)
Non-waiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder
shall operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting
any other provision of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any
provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts
as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including
those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing
any of its rights, powers or remedies hereunder.

 

(h)
Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company
shall be delivered in accordance with the notice provisions of the Purchase Agreement.

 

(i)
Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability
of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted
by the Company or by creditors of the Company.

 

(j)
Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages,
will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not
be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees
to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate or that there
is no irreparable harm and not to require the posting of a bond or other security.

 

    	 	11	 

     

    

 

(k)
Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby
shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted
assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant
and shall be enforceable by the Holder or Holders of Warrant Shares.

 

(l)
Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company
and Holders of 100% of the outstanding Warrants issued pursuant to the Purchase Agreement.

 

(m)
Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective
and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such
provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions
or the remaining provisions of this Warrant.

 

(n)
Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be
deemed a part of this Warrant.

  

    	 	12	 

     

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first
above indicated.

 

	 	27
    Health Holdings Corp.
	 	 	 
	 	By:	 
	 	Name:
    	Joseph
    Frontiere
	 	Title:
    	Chief
    Executive Officer

 

    	 	13	 

     

    

 

NOTICE
OF EXERCISE

 

To:
27 Health Holdings Corp.

 

(1)
The undersigned hereby elects to purchase ___________ Warrant Shares of the Company pursuant to the terms of the attached Warrant
(only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer
taxes, if any.

 

(2)
Payment shall take the form of (check applicable box):

 

[  ] in lawful money of the United States; or

 

[  ] [if permitted] the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in
Section 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the
cashless exercise procedure set forth in Section 2(c).

 

(3)
Please issue a certificate or certificates representing said Warrant Shares in the name of the undersigned or in such other name
as is specified below:

 

_______________________________

 

(4)
After giving effect to this Notice of Exercise, the undersigned will not have exceeded the Beneficial Ownership Limitation.

 

The
Warrant Shares shall be delivered to the following DWAC Account Number or by physical delivery of a certificate to:

 

_______________________________

 

_______________________________

 

_______________________________

 

 

[SIGNATURE
OF HOLDER]

 

Name
of Investing Entity: ______________________________________________________

Signature
of Authorized Signatory of Investing Entity: __________________________________

Name
of Authorized Signatory: ____________________________________________

Title
of Authorized Signatory: _______________________________________

Date:
_______________________________________________________________

 

    	 	14	 

     

    

 

ASSIGNMENT
FORM

 

(To
assign the foregoing warrant, execute

this
form and supply required information.

Do
not use this form to exercise the warrant.)

 

27
Health Holdings Corp.

 

FOR
VALUE RECEIVED, [____] all of or [_______] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned
to

 

_______________________________________________
whose address is

 

_______________________________________________________________

 

_______________________________________________________________

 

	 	Dated:
    ______________, _______	 

 

	 	Holder’s
    Signature:	_____________________________	 
	 	 	 	 
	 	Holder’s
    Address:	_____________________________	 
	 	 	 	 
	 	 	 	 

 

Signature
Guaranteed: ___________________________________________

 

NOTE:
The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration
or enlargement or any change whatsoever, and must be guaranteed by a bank or trust company. Officers of corporations and those
acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.

 

    	 	15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00312-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00312-of-00352.parquet"}]]